ANALOGUES OF GLP-1

Abstract: The present invention is directed to peptide analogues of glucagon-like peptide-1, the pharmaceutically-acceptable salts thereof, to methods of using such analogues to treat mammals and to pharmaceutical compositions useful therefor comprising said analogues.

Description: ANALOGUES OF GLP-1 Background of the Invention The present invention is directed to peptide analogues of glucagon-like peptide-1 , the pharmaceutically-acceptable salts thereof, to methods of using such analogues to treat mammals and to pharmaceutical compositions useful therefor comprising said analogues. Glucagon-like peptide-1 (7-36) amide (GLP-1 ) is synthesized in the intestinal L-cells by tissue-specific post-translational processing of the glucagon precursor preproglucagon (Vamdell, J.M., et al., J. Histochem Cytochem, 1985:33:1080-6) and is released into the circulation in response to a meal. The plasma concentration of GLP-1 rises from a fasting level of approximately 15 pmol/L to a peak postprandial level of 40 pmol/L. It has been demonstrated that, for a given rise in plasma glucose concentration, the increase in plasma insulin is approximately threefold greater when glucose is administered orally compared with intravenously (Kreymann, B., et al., Lancet 1987:2, 1300-4). This alimentary enhancement of insulin release, known as the incretin effect, is primarily humoral and GLP-1 is now thought to be the most potent physiological incretin in humans. In addition to the insulinotropic effect, GLP-1 suppresses glucagon secretion, delays gastric emptying (Wettergren A., et al., Dig Dis Sci 1993:38:665-73) and may enhance peripheral glucose disposal (D'Alessio, D.A. et al., J. Clin invest 1994:93:2293-6). In 1994, the therapeutic potential of GLP-1 was suggested following the observation that a single subcutaneous (s/c) dose of GLP-1 could completely normalize postprandial glucose levels in patients with non-insulin-dependent diabetes mellitus (NIDDM) (Gutniak, M.K., et al., Diabetes Care 1994:17:1039-44). This effect was thought to be mediated both by increased insulin release and by a reduction in glucagon secretion. Furthermore, an intravenous infusion of GLP-1 has been shown to delay postprandial gastric emptying in patients with NIDDM (Williams, B., et al., J. Clin Endo Metab 1996:81 :327-32). Unlike sulphonylureas, the insulinotropic action of GLP-1 is dependent on plasma glucose concentration (Holz, G.G. 4 th , et al., Nature 1993:361 :362-5). Thus, the loss of GLP-1 -mediated insulin release at low plasma glucose concentration protects against severe hypoglycemia. This combination of actions gives GLP-1 unique potential therapeutic advantages over other agents currently used to treat NIDDM. Numerous studies have shown that when given to healthy subjects, GLP-1 potently influences glycemic levels as well as insulin and glucagon concentrations (Orskov, C, Diabetoiogia 35:701-711 , 1992; Hoist, J.J., et al., Potential of GLP-1 in diabetes management in Glucagon III, Handbook of Experimental Pharmacology, Lefevbre PJ, Ed. Berlin, Springer Verlag, 1996, p. 311-326), effects which are glucose dependent (Kreymann, B., et al., Lancet ii: 1300-1304, 1987; Weir, G.C., et al., Diabetes 38:338-342, 1989). Moreover, it is also effective in patients with diabetes (Gutniak, M., N. Engl J Med 226:1316-1322, 1992; Nathan, D.M., et al., Diabetes Care 15:270-276, 1992), normalizing blood glucose levels in type 2 diabetic subjects (Nauck, M.A., et al., Diagbetologia 36:741-744, 1993), and improving glycemic control in type 1 patients (Creutzfeldt, W.O., et al., Diabetes Care 19:580-586, 1996), raising the possibility of its use as a therapeutic agent. GLP-1 is, however, metabolically unstable, having a plasma half-life (t 1/2 ) of only 1-2 min in vivo. Exogenously administered GLP-1 is also rapidly degraded (Deacon, OF., et al., Diabetes 44:1126-1131 , 1995). This metabolic instability limits the therapeutic potential of native GLP-1. Hence, there is a need for GLP-1 analogues that are more active or are more metabolically stable than native GLP-1. Summary of the Invention In one aspect, the present invention is directed to a compound of formula (I), (R 2 R 3 )-A 7 -A 8 -A 9 -A 10 -A 11 -A 12 -A 13 -A 4 -A 15 -A 16 -A 17 -A 18 -A 19 -A 20 -A 21 -A 22 -A 23 -A 24 -A 25 -A 26 -A 27 - Λ 28_ Λ 29_ Λ 30_ Λ 31 _ Λ 32_ Λ 33_ Λ 34_ Λ 35_ Λ 36_ Λ 37_ Λ 38_ Λ 39_p 1 (I) wherein A 7 is L-His, Ura, Paa, Pta, Amp, Tma-His, des-amino-His, or deleted; A 8 is Ala, D-Ala, Aib, Ace, N-Me-Ala, N-Me-D-Ala or N-Me-Gly; A 9 is Glu, N-Me-Glu, N-Me-Asp or Asp; A 10 is Gly, Ace, β-Ala or Aib; A 11 is Thr or Ser; A 12 is Phe, Ace, Aic, Aib, 3-Pal, 4-Pal, β-Nal, Cha, Trp or X 1 -Phe; A 13 is Thr or Ser; A 14 is Ser or Aib; A 15 is Asp or Glu; A 16 is Val, Ace, Aib, Leu, lie, Tie, Nle, Abu, Ala or Cha; A 17 is Ser or Thr; A 18 is Ser or Thr; A 19 s Tyr, Cha, Phe, 3-Pal, 4-Pal, Aec, β-Nal or X 1 -Phe; A 20 s Leu, Ace, Aib, Nle, lie, Cha, Tie, Val, Phe or X 1 -Phe; A 21 s Glu or Asp; A 22 s Gly, Aec, β-Ala, Glu or Aib; A 23 s Gin, Asp, Asn or Glu; AA 2244 is Ala, Aib, Val, Abu, Tie or Aec; A 25 s Ala, Aib, Val, Abu, Tie, Aec, Lys, Arg, hArg, Orn, HN-CH((CH 2 ) n -N(R 10 R 11 ))- C(O) or HN-CH((CH 2 ) e -X 3 )-C(O); A 26 is Lys, Arg, hArg, Orn, HN-CH((CH 2 ) n -N(R 10 R 11 ))-C(O) or HN-CH((CH 2 ) e -X 3 )- C(O); A 27 is Glu Asp, Leu, Aib or Lys; A 28 is Phe, Pal, β-Nal, X 1 -Phe, Aic, Aec, Aib, Cha or Trp; A 29 is lie, Aec, Aib, Leu, Nle, Cha, Tie, Val, Abu, Ala or Phe; A 30 is Ala, Aib or Ace; A 31 is Trp, β-Nal, 3-Pal, 4-Pal, Phe, Ace, Aib or Cha; A 32 is Leu, Ace, Aib, Nle, lie, Cha, Tie, Phe, X 1 -Phe or Ala; A 33 is Val, Aec, Aib, Leu, lie, Tie, Nle, Cha, Ala, Phe, Abu, Lys or X 1 -Phe; A 34 is Lys, Arg, hArg, Orn, HN-CH((CH 2 ) n -N(R 10 R 11 ))-C(O) or HN-CH((CH 2 ) e -X 3 )- C(O); A 35 is Gly, β-Ala, D-Ala, Gaba, Ava, HN-(CH 2 ) m -C(O), Aib, Aec or a D-amino acid; A 36 is L- or D-Arg, D- or L-Lys, D- or L-hArg, D- or L-Orn, HN-CH((CH 2 ) n -N(R 10 R 11 ))- C(O), HN-CH((CH 2 ) e -X 3 )-C(O) or deleted; A 37 is Gly, β-Ala, Gaba, Ava, Aib, Ace, Ado, Arg, Asp, Aun, Aec, HN-(CH 2 ) m -C(O), HN-CH((CH 2 ) n -N(R 10 R 11 ))-C(O), a D-amino acid, or deleted; A 38 is D- or L-Lys, D- or L-Arg, D- or L-hArg, D- or L-Orn, HN-CH((CH 2 ) n -N(R 10 R 11 ))- C(O), HN-CH((CH 2 ) e -X 3 )-C(O) Ava, Ado, Aec or deleted; A 39 is D- or L-Lys, D- or L-Arg, HN-CH((CH 2 ) n -N(R 10 R 11 ))-C(O), Ava, Ado, or Aec; X 1 for each occurrence is independently selected from the group consisting of (C,- C 6 )alkyl, OH and halo; R 1 is OH, NH 2 , (C r C 30 )alkoxy, or NH-X 2 -CH 2 -Z°, wherein X 2 is a (C r C 12 )hydrocarbon moiety, and Z° is H, OH, CO 2 H or CONH 2 ; or -C(O)-NHR 12 , wherein X 4 is, independently for each occurrence, -C(O)-, -NH- C(O)- or -CH 2 -, and wherein f is, independently for each occurrence, an integer from 1 to 29 inclusive; each of R 2 and R 3 is independently selected from the group consisting of H, (C C 30 )alkyl, (C 2 -C 30 )alkenyl, phenyl(C C 30 )alkyl, naphthyl(C r C 30 )alkyl, hydroxy(C 1 - C 30 )alkyl, hydroxy(C 2 -C 30 )alkenyl, and hydroxynaphthyl(C 1 -C 30 )alkyl; or one of R 2 and R 3 is ( CH 3)2- N"C N ( C 3 )2 ] (C Y(CH 2 ) r -N N-(CH 2 ) q SO 2 - C 30 )acyl, (C r C 30 )alkylsulfonyl, C(O)X 5 , , or Y(CH 2 ) r -N si N-(CH 2 ) q -CO- \ / ; wherein Y is H, OH or NH 2 ; r is 0 to 4; q is 0 to 4; and X 5 is (C C 30 )a\ky\, (C 2 -C 30 )alkenyl, phenyl(C r C 30 )alkyl, naphthyl(C 1 -C 30 )alkyl, hydroxy(C 1 -C 30 )alkyl, hydroxy(C 2 -C 30 )alkenyl, hydroxypheny C CsoJalkyl or hydroxynaphthyl(C 1 -C 30 )alkyl; e is, independently for each occurrence, an integer from 1 to 4 inclusive; m is, independently for each occurrence, an integer from 5 to 24 inclusive; n is, independently for each occurrence, an integer from 1 to 5, inclusive; each of R 10 and R 11 is, independently for each occurrence, H, (C 1 -C 30 )alkyl, (C r C 30 )acyl, (C 1 -C 30 )alkylsulfonyl, -C((NH)(NH 2 )) or -C(0)-CH 2 — N N— (CH 2 ) f -CH 3 ; and R 12 and R 13 each is, independently for each occurrence, (C 1 -C 30 )alkyl; provided that: when A 7 is Ura, Paa or Pta, then R 2 and R 3 are deleted; when R 10 is (C r C 3 o)ac l, (C r C 30 )alkylsulfonyl, -C((NH)(NH 2 )) or / \ -C(0)-CH 2 — N sj N— (CH 2 ) f -CH 3 \ / , then R 11 is H or (C r C 30 )alkyl; (i) at least one amino acid of a compound of formula (I) is not the same as the native sequence of hGLP-1 (7-36, -37 or -38)NH 2 or hGLP-1 (7-36, -37 or -38)OH; (ii) a compound of formula (I) is not an analogue of hGLP-1 (7-36, -37 or -38)NH 2 or hGLP-1 (7-36, -37 or -38)OH wherein a single position has been substituted by Ala; (iii) a compound of formula (I) is not (Arg 26 - 34 , Lys 38 )hGLP-1 (7-38)-E, (Lys 26 (N E - alkanoyl))hGLP-1 (7-36, -37 or -38)-E, (Lys 34 (N ε -alkanoyl))hGLP-1 (7-36, -37 or - 38)-E, (Lys 26 ' 34 -bis(N E -alkanoyl))hGLP-1 (7-36, -37 or -38)-E, (Arg 26 , Lys 34 (Nε- alkanoyl))hGLP-1 (8-36, -37 or -38)-E, (Arg 2634 , Lys 36 (Nε-alkanoyl))hGLP-1 (7-36, -37 or -38)-E or (Arg 2634 , Lys 38 (N ε -alkanoyl))hGLP-1 (7-38)-E, wherein E is -OH or -NH 2 ; (iv) a compound of formula (I) is not Z 1 -hGLP-1 (7-36, -37 or -38)-OH, Z 1 -hGLP-1 (7- 36, -37 or -38)-NH 2 , wherein Z 1 is selected from the group consisting of: (a) (Arg 26 ), (Arg 34 ), (Arg 2634 ), (Lys 36 ), (Arg 26 , Lys 36 ), (Arg 34 , Lys 36 ), (D-Lys 36 ), (Arg 36 ), (D-Arg 36 ), (Arg 2634 , Lys 36 ) or (Arg 2636 , Lys 34 ); (b) (Asp 21 ); (c) at least one of (Aib 8 ), (D-Ala 8 ) and (Asp 9 ); and (d) (Tyr 7 ), (N-acyl-His 7 ), (N-alkyl-His 7 ), (N-acyl-D-His 7 ) or (N-alkyl-D-His 7 ); (v) a compound of formula (I) is not a combination of any two of the substitutions listed in groups (a) to (d); and (vi) a compound of formula (I) is not (N-Me-Ala 8 )hGLP-1 (8-36 or -37), (Glu 15 )hGLP- 1 (7-36 or -37), (Asp 21 )hGLP-1(7-36 or -37) or (Phe 31 )hGLP-1 (7-36 or -37) or a pharmaceutically acceptable salt thereof. A preferred group of compounds of the immediately foregoing compound is where A 11 is Thr; A 13 is Thr; A 15 is Asp; A 17 is Ser; A 18 is Ser or Lys; A 21 is Glu; A 23 is Gin or Glu; A 27 is Glu, Leu, Aib or Lys; and A 31 is Trp, Phe or β-Nal; or a pharmaceutically acceptable salt thereof. A preferred group of compounds of the immediately foregoing group of compounds is where A 9 is Glu, N-Me-Glu or N-Me-Asp; A 12 is Phe, Ace, β-Nal or Aic; A 16 is Val, Aec or Aib; A 19 is Tyr or β-Nal; A 20 is Leu, Aec or Cha; A 24 is Ala, Aib or Aec; A 25 is Ala, Aib, Ace, Lys, Arg, hArg, Orn, HN-CH((CH 2 ) n -N(R 10 R 11 ))-C(O) or HN-CH((CH 2 ) e -X 3 )-C(O); A 28 is Phe or β-Nal; A 29 is lie or Ace; A 30 is Ala or Aib; A 32 is Leu, Ace or Cha; and A 33 is Val, Lys or Ace; or a pharmaceutically acceptable salt thereof. A preferred group of compounds of the immediately foregoing group of compounds is where A 8 is Ala, D-Ala, Aib, A6c, A5c, N-Me-Ala, N-Me-D-Ala or N- Me-Gly; A 10 is Gly; A 12 is Phe, β-Nal, A6c or A5c; A 16 is Val, A6c or A5c; A 20 is Leu, A6c, A5c or Cha; A 22 is Gly, β-Ala, Glu or Aib; A 24 is Ala or Aib; A 29 is lie, A6c or A5c; A 32 is Leu, A6c, A5c or Cha; A 33 is Val, Lys, A6c or A5c; A 35 is Aib, β-Ala, Ado, A6c, A5c, D-Arg or Gly; and A 37 is Gly, Aib, β-Ala, Ado, D-Ala Ava, Asp, Aun, D- Asp, D-Arg, Aec, HN-CH((CH 2 ) n -N(R 10 R 11 ))-C(O) or deleted; or a pharmaceutically acceptable salt thereof. A preferred group of compounds of the immediately foregoing group of compounds is where X 4 for each occurrence is -C(O)-; and R 1 is OH or NH 2 ; or a pharmaceutically acceptable salt thereof. A preferred group of compounds of the immediately foregoing group of compounds or a pharmaceutically acceptable salt thereof is where R 2 is H and R 3 is (CrC∞Jalkyl, (C 2 -C 3 o)alkenyl, (CrCgoJacyl, (C r C M )alkylsulfonyl, HO-(CH 2 ) 2 -N N-(CH 2 ) 2 SO 2 - HO-(CH 2 ) 2 -N N-CH 2 -CO- or H 2 N-(CH 2 ) 2 -N N-CH 2 -CO- A preferred compound of the formula (I) is where A 8 is Ala, D-Ala, Aib, A6c, A5c, N-Me-Ala, N-Me-D-Ala or N-Me-Gly; A 10 is Gly; A 12 is Phe, β-Nal A6c or A5c; A 16 is Val, A6c or A5c; A 20 is Leu, A6c, A5c or Cha; A 22 is Gly, β-Ala, Glu or Aib; A 24 is Ala or Aib; A 29 is lie, A6c or A5c; A 32 is Leu, A6c, A5c or Cha; A 33 is Val, Lys, A6c or A5c; A 35 is Aib, β-Ala, Ado, A6c, A5c D-Arg or Gly; and A 37 is Gly, Aib, β-Ala, Ado, D-Ala, Ava, Asp, Aun, D-Asp, D-Arg, Aec, HN-CH((CH 2 ) n -N(R 10 R 1 ))-C(O) or deleted; X 4 for each occurrence is -C(O)-; e for each occurrence is independently 1 or 2; R 1 is OH or NH 2 ; R 10 is (C 1 -C 30 )acyl, (C 1 -C 30 )alkylsulfonyl or / ~ Λ -C(O)-CH — N N— (CH 2 ) f -CH 3 , and R 11 is H; or a pharmaceutically acceptable salt thereof. More preferred of the immediately foregoing compounds is where R 10 is (C 4 - -C(0)-CH — N N— (CH 2 ) f -CH 3 C 20 )acyl, (C 4 -C 20 )alkylsulfonyl or , or a pharmaceutically acceptable salt thereof. A more preferred compound of formula (I) is where said compound is of the formula: (Aib 835 )hGLP-1 (7-36)NH 2 , ((Nα-HEPES-His) 7 , Aib 835 )hGLP-1 (7-36)NH 2 , ((Nα-HEPA-His) 7 , Aib 835 )hGLP-1 (7-36)NH 2 , (Aib 8 , β -Ala 35 )hGLP-1 (7-36)NH 2 , (Aib 835 , Arg 2634 , Lys 36 (N ε -tetradecanoyl))hGLP-1 (7-36)NH 2 , (Aib 8 - 35 , Arg 26 , Lys 34 (Nε-tetradecanoyl))hGLP-1 (7-36)NH 2 , (Aib 8 ' 3537 , Arg 2634 , Lys 38 (N ε -tetradecanoyl))hGLP-1(7-38)NH 2 , (Aib 835 , Arg 2634 , Lys 36 (N ε -decanoyl))hGLP-1 (7-36)NH 2 , (Aib 835 , Arg 2634 , Lys 36 (N ε -dodecanesulfonyl))hGLP-1 (7-36)NH 2 , (Aib 835 , Arg 2634 , Lys 36 (N ε -(2-(4-tetradecyl-1 -piperazine)-acetyl)))hGLP-1 (7-36)NH 2 , (Aib 835 , Arg 2634 , Asp 36 (1-(4-tetradecyl-piperazine)))hGLP-1 (7-36)NH 2 , (Aib 835 , Arg 2634 , Asp 36 (1-tetradecylamino))hGLP-1 (7-36)NH 2 , (Aib 835 , Arg 2634 , Lys 36 (N ε -tetradecanoyl),β-Ala 37 )hGLP-1 (7-37)-OH or (Aib 835 , Arg 2634 , Lys 36 (N ε -tetradecanoyl))hGLP-1 (7-36)-OH, or a pharmaceutically acceptable salt thereof . More preferred of the immediately foregoing group of compounds is a compound of the formula: (Aib 8 ' 35 )hGLP-1 (7-36)NH 2 , (Aib 8 , β-Ala 35 )hGLP-1 (7-36)NH 2 , (Aib 835 , Arg 26 , Lys 34 (N ε -tetradecanoyl))hGLP-1 (7-36)NH 2 , (Aib 8 ' 3537 , Arg 2634 , Lys 38 (N E -tetradecanoyl))hGLP-1 (7-38)NH 2 , (Aib 835 , Arg 2634 , Lys 36 (N ε -decanoyl))hGLP-1 (7-36)NH 2 , or (Aib 8 ' 35 , Arg 26 ' 34 , Lys 36 (N ε -tetradecanoyl),β-Ala 37 )hGLP-1 (7-37) -OH, or a pharmaceutically acceptable salt thereof. Another more preferred compound of formula (I) is where said compound is of the formula: (Aib 835 , A6c 32 )hGLP-1 (7-36)NH 2 ; (Aib 835 , Glu 23 )hGLP-1 (7-36)NH 2 ; (Aib 8 ' 2435 )hGLP-1 (7-36)NH 2 ; (Aib 835 , Glu 23 , A6c 32 )hGLP-1 (7-36)NH 2 ; (Aib 8 , Glu 23 , β-Ala 35 )hGLP-1 (7-36)NH 2 ; (Aib 835 , Arg 2634 )hGLP-1 (7-36)NH 2 ; (Aib 835 , Arg 2634 , Lys 36 (N ε -octanoyl))hGLP-1 (7-36)NH 2 ; (Aib 835 , Arg 2634 , Lys 36 (N ε -decanoyl))hGLP-1 (7-36)OH; (Aib 835 , Lys 25 , Arg 2634 , Lys 36 (N ε -decanoyl))hGLP-1 (7-36)OH; (Aib 8 , Arg 2634 , β-Ala 35 , Lys 36 (N ε -Aec-decanoyl))hGLP-1 (7-36)NH 2 ; (Aib 8 ' 35 ,Arg 26 ' 34 , Ava 37 , Ado 38 )hGLP-1 (7-38)NH 2 ; (Aib 8 ' 35 ,Arg 26 ' 34 , Asp 37 , Ava 38 , Ado 39 )hGLP-1 (7-39)NH 2 ; (Aib 8 ' 35 ,Arg 26 ' 34 , Aun 37 )hGLP-1 (7-37)NH 2 ; (Aib 8 ' 17 - 35 ,)hGLP-1 (7-36)NH 2 ; (Aib 8 ,Arg 26 ' 34 , β-Ala 35 , D-Asp 37 , Ava 38 , Aun 39 )hGLP-1 (7-39)NH 2 ; (Gly 8 , β -Ala 35 )hGLP-1 (7-36)NH 2 ; (Ser 8 , β-Ala 35 )hGLP-1(7-36)NH 2 ; (Aib 8 , Glu 2223 , β-Ala 35 )hGLP-1(7-36)NH 2 ; (Gly 8 , Aib 35 )hGLP-1 (7-36)NH 2 ; (Aib 8 , Lys 18 , β-Ala 35 )hGLP-1(7-36)NH 2 ; (Aib 8 , Leu 27 , β-Ala 35 )hGLP-1 (7-36)NH 2 ; (Aib 8 , Lys 33 , β-Ala 35 )hGLP-1 (7-36)NH 2 ; (Aib 8 , Lys 18 , Leu 27 , β-Ala 35 )hGLP-1 (7-36)NH 2 ; (Aib 8 , D-Arg 36 )hGLP-1 (7-36)NH 2 ; (Aib 8 , β-Ala 35 , D-Arg 37 )hGLP-1 (7-37)NH 2 ; (Aib 827 , β-Ala 35 )hGLP-1 (7-36)NH 2 ; (Aib 827 , β-Ala 35 ' 37 , Arg 38 )hGLP-1 (7-38)NH 2 ; (Aib 827 , β -Ala 35 ' 37 , Arg 38 ' 39 )hGLP-1 (7-39)NH 2 ; (Aib 8 , Lys 1827 , β-Ala 35 )hGLP-1 (7-36)NH 2 ; (Aib 8 , Lys 27 , β-Ala 35 )hGLP-1 (7-36)NH 2 ; (Aib 8 , β-Ala 35 , Arg 38 )hGLP-1 (7-38)NH 2 ; (Aib 8 , Arg 26 ' 34 , β-Ala 35 ,)hGLP-1 (7-36)NH 2 ; (Aib 8 , D-Arg 35 )hGLP-1 (7-36)NH 2 ; (Aib 8 , β-Ala 35 , Arg 37 )hGLP-1 (7-37)NH 2 ; (Aib 8 , Phe 31 , β-Ala 35 )hGLP-1(7-36)NH 2 ; (Aib 8 35 , Phe 31 )hGLP-1 (7-36)NH 2 ; (Aib 835 , Nal 31 )hGLP-1(7-36)NH 2 ; (Aib 8 - 35 , Nal 2831 )hGLP-1 (7-36)NH 2 ; (Aib 835 , Arg 26 ' 34 , Nal 31 )hGLP-1 (7-36)NH 2 ; (Aib 835 , Arg 2634 , Phe 31 )hGLP-1 (7-36)NH 2 ; (Aib 835 , Nal 19 ' 31 )hGLP-1 (7-36)NH 2 ; (Aib 835 , Nal 2 ' 31 )hGLP-1 (7-36)NH 2 ; (Aib 835 , Lys 36 (N ε -decanoyl))hGLP-1 (7-36) NH 2 ; (Aib 835 , Arg 34 , Lys 26 (N e -decanoyl))hGLP-1(7-36)NH 2 ; (Aib 835 , Arg 26 ' 34 , Lys 36 (N ε -dodecanoyl))hGLP-1 (7-36)NH 2 ; (Aib 8 ,B-Ala 35 , Ser^O-decanoyl^hGLPI (7-37)-NH 2 ; (Aib 827 , β-Ala 35 ' 37 , Arg 38 , Lys 39 (N ε -octanoyl))hGLP-1 (7-39)NH 2 ; (Aib 8 , Arg 2634 , β-Ala 35 , Lys 37 (N ε -octanoyl))hGLP-1 (7-37)NH 2 ; (Aib 8 , Arg 2634 , β-Ala 35 , Lys 37 (N ε -decanoyl))hGLP-1 (7-37)NH 2 ; or (Aib 8 , Arg 2634 , β-Ala 35 , Lys 37 (N ε -tetradecanoyl))hGLP-1 (7-37)NH 2 ; or a pharmaceutically acceptable salt thereof. Another more preferred compound of formula (I) is each of the compounds that are specifically enumerated hereinbelow in the Examples section of the present disclosure, or a pharmaceutically acceptable salt thereof. In another aspect, the present invention provides a pharmaceutical composition comprising an effective amount of a compound of formula (I) as defined hereinabove or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent. In yet another aspect, the present invention provides a method of eliciting an agonist effect from a GLP-1 receptor in a subject in need thereof which comprises administering to said subject an effective amount of a compound of formula (I) as defined hereinabove or a pharmaceutically acceptable salt thereof. In a further aspect, the present invention provides a method of treating a disease selected from the group consisting of Type I diabetes, Type II diabetes, obesity, glucagonomas, secretory disorders of the airway, metabolic disorder, arthritis, osteoporosis, central nervous system disease, restenosis, neurodegenerative disease, renal failure, congestive heart failure, nephrotic syndrome, cirrhosis, pulmonary edema, hypertension, and disorders wherein the reduction of food intake is desired, in a subject in need thereof which comprises administering to said subject an effective amount of a compound of formula (I) as defined hereinabove or a pharmaceutically acceptable salt thereof. A preferred method of the immediately foregoing method is where the disease being treated is Type I diabetes or Type II diabetes. With the exception of the N-terminal amino acid, all abbreviations (e.g. Ala) of amino acids in this disclosure stand for the structure of -NH-CH(R)-CO-, wherein R is the side chain of an amino acid (e.g., CH 3 for Ala). For the N-terminal amino acid, the abbreviation stands for the structure of (R 2 R 3 )-N-CH(R)-CO-, wherein R is a side chain of an amino acid and R 2 and R 3 are as defined above, except when A 7 is Ura, Paa or Pta, in which case R 2 and R 3 are not present since Ura, Paa and Pta are considered here as des-amino amino acids. Amp, β-Nal, Nle, Cha, 3-Pal, 4-Pal and Aib are the abbreviations of the following α-amino acids: 4-amino- phenylalanine, β-(2-naphthyl)alanine, norleucine, cyclohexylalanine, β-(3- pyridinyl)alanine, β-(4-pyridinyl)alanine and α-aminoisobutyric acid, respectively. Other amino acid definitions are: Ura is urocanic acid; Pta is (4-pyridylthio) acetic acid; Paa is ans-3-(3-pyridyl) acrylic acid; Tma-His is N,N-tetramethylamidino- histidine; N-Me-Ala is N-methyl-alanine; N-Me-Gly is N-methyl-glycine; N-Me-Glu is N-methyl-glutamic acid; Tie is terf-butylglycine; Abu is α-aminobutyric acid; Tba is tetf-butylalanine; Orn is omithine; Aib is α-aminoisobutyric acid; β-Ala is β-alanine; Gaba is γ-aminobutyric acid; Ava is 5-aminovaleric acid; Ado is 12- aminododecanoic acid, Aic is 2-aminoindane-2-carboxylic acid; Aun is 11- aminoundecanoic acid; and Aec is 4-(2-aminoethyl)-1-carboxymethyl-piperazine, represented by the structure: What is meant by Aec is an amino acid selected from the group of -amino- 1-cyclopropanecarboxylic acid (A3c); 1-amino-1-cyclobutanecarboxylic acid (A4c); 1-amino-1-cyclopentanecarboxylic acid (A5c); 1-amino-1-cyciohexanecarboxylic acid (A6c); 1-amino-1-cycloheptanecarboxylic acid (A7c); 1-amino-1- cyclooctanecarboxylic acid (A8c); and 1-amino-1-cyclononanecarboxylic acid (A9c). In the above formula, hydroxyalkyl, hydroxyphenylalkyl, and hydroxynaphthylalkyl may contain 1-4 hydroxy substituents. COX 5 stands for -C=O X 5 . Examples of - C=O X 5 include, but are not limited to, acetyl and phenylpropionyl. What is meant by Lys(N ε -alkanoyl) is represented by the following structure: What is meant by Lys(Nε-alkylsulfonyl) is represented by the following structure: . What is meant by Lys(N ε -(2-(4-alkyl-1-piperazine)-acetyl)) is represented by the following structure: What is meant by Asp(1-(4-alkyl-piperazine)) is represented by the following structure: What is meant by Asp(l-alkylamino) is represented by the following structure: What is meant by Lys(Nε-Aec-alkanoyl) is represented by the structure: variable n in the foregoing structures is 1-30. What is meant by Lys (Nε-ace-alkanoyI) is represented by the structure: The full names for other abbreviations used herein are as follows: Boc for t- butyloxycarbonyl, HF for hydrogen fluoride, Fm for formyl, Xan for xanthyl, Bzl for benzyl, Tos for tosyl, DNP for 2,4-dinitrophenyl, DMF for dimethylformamide, DCM for dichloromethane, HBTU for 2-(1 H-Benzotriazol-1-yl)-1 ,1 ,3,3-tetramethyl uronium hexafluorophosphate, DIEA for diisopropylethylamine, HOAc for acetic acid, TFA for trifluoroacetic acid, 2CIZ for 2-chlorobenzyloxycarbonyl, 2BrZ for 2- bromobenzyloxycarbonyl, OcHex for O-cyclohexyl, Fmoc for 9- fluorenylmethoxycarbonyl, HOBt for N-hydroxybenzothazole and PAM resin for 4- hydroxymethylphenylacetamidomethyl resin. The term "halo" encompasses fluoro, chloro, bromo and iodo. The term "(C 1 -C 30 )hydrocarbon moiety" encompasses alkyl, alkenyl and alkynyl, and in the case of alkenyl and alkynyl there are C 2 -C 30 . A peptide of this invention is also denoted herein by another format, e.g., (A5c 8 )hGLP-1 (7-36)NH 2 , with the substituted amino acids from the natural sequence placed between the first set of parentheses (e.g., A5c 8 for Ala 8 in hGLP- 1 ). The abbreviation GLP-1 means glucagon-like peptide-1 ; hGLP-1 means human glucagon-like peptide-1. The numbers between the parentheses refer to the number of amino acids present in the peptide (e.g., hGLP-1 (7-36) is amino acids 7 through 36 of the peptide sequence for human GLP-1 ). The sequence for hGLP- 1 (7-37) is listed in Mojsov, S., Int. J. Peptide Protein Res,. 40, 1992, pp. 333-342. The designation "NH 2 " in hGLP-1 (7-36)NH 2 indicates that the C-terminus of the peptide is amidated. hGLP-1 (7-36) means that the C-terminus is the free acid. In hGLP-1 (7-38), residues in positions 37 and 38 are Gly and Arg, respectively. Detailed Description The peptides of this invention can be prepared by standard solid phase peptide synthesis. See, e.g., Stewart, J.M., et al., Solid Phase Synthesis (Pierce Chemical Co., 2d ed. 1984). The substituents R 2 and R 3 of the above generic formula may be attached to the free amine of the N-terminal amino acid by standard methods known in the art. For example, alkyl groups, e.g., (C 1 -C 30 )alkyl, may be attached using reductive alkylation. Hydroxyalkyl groups, e.g., (d- C 30 )hydroxyalkyl, may also be attached using reductive alkylation wherein the free hydroxy group is protected with a t-butyl ester. Acyl groups, e.g., COE 1 , may be attached by coupling the free acid, e.g., E 1 COOH, to the free amine of the N- terminal amino acid by mixing the completed resin with 3 molar equivalents of both the free acid and diisopropylcarbodiimide in methylene chloride for one hour. If the free acid contains a free hydroxy group, e.g., p-hydroxyphenylpropionic acid, then the coupling should be performed with an additional 3 molar equivalents of HOBT. When R 1 is NH-X 2 -CH 2 -CONH 2 , (i.e., Z°=CONH 2 ), the synthesis of the peptide starts with BocHN-X 2 -CH 2 -COOH which is coupled to the MBHA resin. If R 1 is NH-X 2 -CH 2 -COOH, (i.e., Z°=COOH) the synthesis of the peptide starts with Boc-HN-X 2 -CH 2 -COOH which is coupled to PAM resin. For this particular step, 4 molar equivalents of Boc-HN-X 2 -COOH, HBTU and HOBt and 10 molar equivalents of DIEA are used. The coupling time is about 8 hours. The protected amino acid 1-(N-tert-butoxycarbonyl-amino)-1-cyclohexane- carboxylic acid (Boc-A6c-OH) was synthesized as follows. 19.1 g (0.133 mol) of 1- amino-1-cyclohexanecarboxylic acid (Acros Organics, Fisher Scientific, Pittsburgh, PA) was dissolved in 200 ml of dioxane and 100 ml of water. To it was added 67 ml of 2N NaOH. The solution was cooled in an ice-water bath. 32.0 g (0.147 mol) of di-tert-butyl-dicarbonate was added to this solution. The reaction mixture was stirred overnight at room temperature. Dioxane was then removed under reduced pressure. 200 ml of ethyl acetate was added to the remaining aqueous solution. The mixture was cooled in an ice-water bath. The pH of the aqueous layer was adjusted to about 3 by adding 4N HCI. The organic layer was separated. The aqueous layer was extracted with ethyl acetate (1 x 100 ml). The two organic layers were combined and washed with water (2 x 150 ml), dried over anhydrous MgSO 4 , filtered, and concentrated to dryness under reduced pressure. The residue was recrystallized in ethyl acetate/hexanes. 9.2 g of the pure product was obtained. 29% yield. Boc-A5c-OH was synthesized in an analogous manner to that of Boc-A6c- OH. Other protected Aec amino acids can be prepared in an analogous manner by a person of ordinary skill in the art as enabled by the teachings herein. In the synthesis of a GLP-1 analogue of this invention containing A5c, A6c and/or Aib, the coupling time is 2 hrs. for these residues and the residue immediately following them. For the synthesis of (Tma-His 7 )hGLP-1 (7-36)NH 2 , HBTU (2 mmol) and DIEA (1.0 ml) in 4 ml DMF are used to react with the N- terminal free amine of the peptide-resin in the last coupling reaction; the coupling time is about 2 hours. The substituents R 2 and R 3 of the above generic formula can be attached to the free amine of the N-terminal amino acid by standard methods known in the art. For example, alkyl groups, e.g., (C,-C 30 )alkyl, can be attached using reductive alkylation. Hydroxyalkyl groups, e.g., (d-Ca^hydroxyalkyl, can also be attached using reductive alkylation wherein the free hydroxy group is protected with a t-butyl ester. Acyl groups, e.g., COX 1 , can be attached by coupling the free acid, e.g., X 1 COOH, to the free amine of the N-terminal amino acid by mixing the completed resin with 3 molar equivalents of both the free acid and diisopropylcarbodiimide in methylene chloride for about one hour. If the free acid contains a free hydroxy group, e.g., p-hydroxyphenylpropionic acid, then the coupling should be performed with an additional 3 molar equivalents of HOBT. A compound of the present invention can be tested for activity as a GLP-1 binding compound according to the following procedure. Cell Culture: RIN 5F rat insulinoma cells (ATCC-# CRL-2058, American Type Culture Collection, Manassas, VA), expressing the GLP-1 receptor, were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal calf serum, and maintained at about 37 °C in a humidifed atmosphere of 5% CO 2 /95% air. Radioligand Binding: Membranes were prepared for radioligand binding studies by homogenization of the RIN cells in 20 ml of ice-cold 50 mM Tris-HCI with a Brinkman Polytron (Westbury, NY) (setting 6, 15 sec). The homogenates were washed twice by centrifugation (39,000 g / 10 min), and the final pellets were resuspended in 50 mM Tris-HCI, containing 2.5 mM MgCI 2 , 0.1 mg/ml bacitracin (Sigma Chemical, St. Louis, MO), and 0.1% BSA. For assay, aliquots (0.4 ml) were incubated with 0.05 nM ( 125 l)GLP-1 (7-36) (-2200 Ci/mmol, New England Nuclear, Boston, MA), with and without 0.05 ml of unlabeled competing test peptides. After a 100 min incubation (25 °C), the bound ( 125 l)GLP-1 (7-36) was separated from the free by rapid filtration through GF/C filters (Brandel, Gaithersburg, MD), which had been previously soaked in 0.5% polyethyleneimine. The filters were then washed three times with 5 ml aliquots of ice-cold 50 mM Tris- HCI, and the bound radioactivity trapped on the filters was counted by gamma spectrometry (Wallac LKB, Gaithersburg, MD). Specific binding was defined as the total ( 125 l)GLP-1 (7-36) bound minus that bound in the presence of 1000 nM GLP1 (7-36) (Bachem, Torrence, CA). The peptides of this invention can be provided in the form of pharmaceutically acceptable salts. Examples of such salts include, but are not limited to, those formed with organic acids (e.g., acetic, lactic, maleic, citric, malic, ascorbic, succinic, benzoic, methanesulfonic, toluenesulfonic, or pamoic acid), inorganic acids (e.g., hydrochloric acid, sulfuric acid, or phosphoric acid), and polymeric acids (e.g., tannic acid, carboxymethyl cellulose, polylactic, polyglycolic, or copolymers of polylactic-glycolic acids). A typical method of making a salt of a peptide of the present invention is well known in the art and can be accomplished by standard methods of salt exchange. Accordingly, the TFA salt of a peptide of the present invention (the TFA salt results from the purification of the peptide by using preparative HPLC, eluting with TFA containing buffer solutions) can be converted into another salt, such as an acetate salt by dissolving the peptide in a small amount of 0.25 N acetic acid aqueous solution. The resulting solution is applied to a semi-prep HPLC column (Zorbax, 300 SB, C-8). The column is eluted with (1 ) 0.1 N ammonium acetate aqueous solution for 0.5 hrs., (2) 0.25N acetic acid aqueous solution for 0.5 hrs. and (3) a linear gradient (20% to 100% of solution B over 30 min.) at a flow rate of 4 ml/min (solution A is 0.25N acetic acid aqueous solution; solution B is 0.25N acetic acid in acetonitrile/water, 80:20). The fractions containing the peptide are collected and lyophilized to dryness. As is well known to those skilled in the art, the known and potential uses of GLP-1 is varied and multitudinous (See, Todd, J.F., et al., Clinical Science, 1998, 95, pp. 325-329; and Todd, J.F. et al., European Journal of Clinical Investigation, 1997, 27, pp.533-536). Thus, the administration of the compounds of this invention for purposes of eliciting an agonist effect can have the same effects and uses as GLP-1 itself. These varied uses of GLP-1 may be summarized as follows, treatment of: Type I diabetes, Type II diabetes, obesity, glucagonomas, secretory disorders of the airway, metabolic disorder, arthritis, osteoporosis, central nervous system diseases, restenosis, neurodegenerative diseases, renal failure, congestive heart failure, nephrotic syndrome, cirrhosis, pulmonary edema, hypertension, and disorders wherein the reduction of food intake is desired. GLP-1 analogues of the present invention that elicit an antagonist effect from a subject can be used for treating the following: hypoglycemia and malabsorption syndrome associated with gastroectomy or small bowel resection. Accordingly, the present invention includes within its scope pharmaceutical compositions comprising, as an active ingredient, at least one of the compounds of formula (I) in association with a pharmaceutically acceptable carrier. The dosage of active ingredient in the compositions of this invention may be varied; however, it is necessary that the amount of the active ingredient be such that a suitable dosage form is obtained. The selected dosage depends upon the desired therapeutic effect, on the route of administration, and on the duration of the treatment. In general, an effective dosage for the activities of this invention is in the range of 1x10 "7 to 200 mg/kg/day, preferably IxlO "4 to 100 mg/kg/day, which can be administered as a single dose or divided into multiple doses. The compounds of this invention can be administered by oral, parenteral (e.g., intramuscular, intraperitoneal, intravenous or subcutaneous injection, or implant), nasal, vaginal, rectal, sublingual or topical routes of administration and can be formulated with pharmaceutically acceptable carriers to provide dosage forms appropriate for each route of administration. Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In such solid dosage forms, the active compound is admixed with at least one inert pharmaceutically acceptable carrier such as sucrose, lactose, or starch. Such dosage forms can also comprise, as is normal practice, additional substances other than such inert diluents, e.g., lubricating agents such as magnesium stearate. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents. Tablets and pills can additionally be prepared with enteric coatings. Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, the elixirs containing inert diluents commonly used in the art, such as water. Besides such inert diluents, compositions can also include adjuvants, such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring and perfuming agents. Preparations according to this invention for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, or emulsions. Examples of non-aqueous solvents or vehicles are propylene glycol, polyethylene glycol, vegetable oils, such as olive oil and corn oil, gelatin, and injectable organic esters such as ethyl oleate. Such dosage forms may also contain adjuvants such as preserving, wetting, emulsifying, and dispersing agents. They may be sterilized by, for example, filtration through a bacteria-retaining filter, by incorporating sterilizing agents into the compositions, by irradiating the compositions, or by heating the compositions. They can also be manufactured in the form of sterile solid compositions which can be dissolved in sterile water, or some other sterile injectable medium immediately before use. Compositions for rectal or vaginal administration are preferably suppositories which may contain, in addition to the active substance, excipients such as coca butter or a suppository wax. Compositions for nasal or sublingual administration are also prepared with standard excipients well known in the art. Further, a compound of this invention can be administered in a sustained release composition such as those described in the following patents and patent applications. U.S. Patent No. 5,672,659 teaches sustained release compositions comprising a bioactive agent and a polyester. U.S. Patent No. 5,595,760 teaches sustained release compositions comprising a bioactive agent in a gelable form. U.S. Application No. 08/929,363 filed September 9, 1997, teaches polymeric sustained release compositions comprising a bioactive agent and chitosan. U.S. Application No. 08/740,778 filed November 1 , 1996, teaches sustained release compositions comprising a bioactive agent and cyclodextrin. U.S. Application No. 09/015,394 filed January 29, 1998, teaches absorbable sustained release compositions of a bioactive agent. U.S. Application No. 09/121 ,653 filed July 23, 1998, teaches a process for making microparticles comprising a therapeutic agent such as a peptide in an oil-in-water process. U.S. Application No. 09/131 ,472 filed August 10, 1998, teaches complexes comprising a therapeutic agent such as a peptide and a phosphorylated polymer. U.S. Application No. 09/184,413 filed November 2, 1998, teaches complexes comprising a therapeutic agent such as a peptide and a polymer bearing a non-polymerizable lactone. The teachings of the foregoing patents and applications are incorporated herein by reference. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Also, all publications, patent applications, patents and other references mentioned herein are incorporated by reference. The following examples describe synthetic methods for making a peptide of this invention, which methods are well-known to those skilled in the art. Other methods are also known to those skilled in the art. The examples are provided for the purpose of illustration and is not meant to limit the scope of the present invention in any manner. Boc-βAla-OH, Boc-D-Arg(Tos)-OH and Boc-D-Asp(OcHex) were purchased from Nova Biochem, San Diego, California. Boc-Aun-OH was purchased from Bachem, King of Prussia, PA. Boc-Ava-OH and Boc-Ado-OH were purchased from Chem-lmpex International, Wood Dale, IL. Boc-Nal-OH was purchased from Synthetech, Inc. Albany, OR. Example 1 (Aib 8 ' 35 )hGLP-1 (7-36)NH 2 The title peptide was synthesized on an Applied Biosystems (Foster City, CA) model 430A peptide synthesizer which was modified to do accelerated Boc- chemistry solid phase peptide synthesis. See Schnolzer, et al., Int. J. Peptide Protein Res., 90:180 (1992). 4-methylbenzhydrylamine (MBHA) resin (Peninsula, Belmont, CA) with the substitution of 0.91 mmol/g was used. The Boc amino acids (Bachem, CA, Torrance, CA; Nova Biochem., LaJolla, CA) were used with the following side chain protection: Boc-Ala-OH, Boc-Arg(Tos)-OH, Boc-Asp(OcHex)- OH, Boc-Tyr(2BrZ)-OH, Boc-His(DNP)-OH, Boc-Val-OH, Boc-Leu-OH, Boc-Gly- OH, Boc-Gln-OH, Boc-lle-OH, Boc-Lys(2CIZ)-OH, Boc-Thr(Bzl)-OH, Boc-Ser(Bzl)- OH, Boc-Phe-OH, Boc-Aib-OH, Boc-Glu(OcHex)-OH and Boc-Trp(Fm)-OH. The synthesis was carried out on a 0.20 mmol scale. The Boc groups were removed by treatment with 100% TFA for 2 x 1 min. Boc amino acids (2.5 mmol) were pre- activated with HBTU (2.0 mmol) and DIEA (1.0 mL) in 4 mL of DMF and were coupled without prior neutralization of the peptide-resin TFA salt. Coupling times were 5 min. except for the Boc-Aib-OH residues and the following residues, Boc- Lys(2CIZ)-OH and Boc-His(DNP)-OH wherein the coupling times were 2 hours. At the end of the assembly of the peptide chain, the resin was treated with a solution of 20% mercaptoethanol/10% DIEA in DMF for 2 x 30 min. to remove the DNP group on the His side chain. The N-terminal Boc group was then removed by treatment with 100% TFA for 2 x 2 min. After neutralization of the peptide-resin with 10% DIEA in DMF (1 x 1 min), the formyl group on the side chain of Trp was removed by treatment with a solution of 15% ethanolamine/ 15% water/ 70% DMF for 2 x 30 min. The peptide-resin was washed with DMF and DCM and dried under reduced pressure. The final cleavage was done by stirring the peptide-resin in 10 mL of HF containing 1 mL of anisole and dithiothreitol (24 mg) at 0°C for 75 min. HF was removed by a flow of nitrogen. The residue was washed with ether (6 x 10 mL) and extracted with 4N HOAc (6 x 10 mL). The peptide mixture in the aqueous extract was purified on reverse-phase preparative high pressure liquid chromatography (HPLC) using a reverse phase VYDAC® C 18 column (Nest Group, Southborough, MA). The column was eluted with a linear gradient (20% to 50% of solution B over 105 min.) at a flow rate of 10 mL/min (Solution A = water containing 0.1 % TFA; Solution B = acetonit le containing 0.1% of TFA). Fractions were collected and checked on analytical HPLC. Those containing pure product were combined and lyophilized to dryness. 135 mg of a white solid was obtained. Purity was 98.6% based on analytical HPLC analysis. Electro-spray mass spectrometer (MS(ES))S analysis gave the molecular weight at 3339.7 (in agreement with the calculated molecular weight of 3339.7). Example 2 ((Nα-HEPES-His) 7 , Aib 8 ' 35 )hGLP-1 (7-36)NH 2 The title compound (HEPES is (4-(2-hydroxyethyi)-1-piperazine- ethanesulfonic acid)) can be synthesized as follows: after assembly of the peptide (Aib 8 ' 35 )hGLP-1 (7-36)NH 2 on MBHA resin (0.20 mmol) according to the procedure of Example 1 , the peptide-resin is treated with 100% TFA (2 x 2 min.) and washed with DMF and DCM. The resin is then neutralized with 0% DIEA in DMF for 2 min. After washing with DMF and DCM, the resin is treated with 0.23 mmol of 2-chloro- 1-ethanesulfonyl chloride and 0.7 mmol of DIEA in DMF for about 1 hour. The resin is washed with DMF and DCM and treated with 1.2 mmol of 2- hydroxyethylpiperazine for about 2 hours. The resin is washed with DMF and DCM and treated with different reagents ((1) 20% mercaptoethanol / 10% DIEA in DMF and (2) 15% ethanolamine / 15% water / 70% DMF) to remove the DNP group on the His side chain and formyl group on the Trp side chain as described above before the final HF cleavage of the peptide from the resin. Example 3 ((N -HEPA-His) 7 , Aib 835 )hGLP-1 (7-36)NH 2 The title compound (HEPA is (4-(2-hydroxyethyl)-1-piperazineacetyl)) can be made substantially according to the procedure described in Example 2 for making ((Nα-HEPES-His) 7 , Aib 8 ' 35 )hGLP-1(7-36)NH 2 except that 2-bromoacetic anhydride is used in place of 2-chloro-1-ethanesulfonyl chloride. Example 4 (Aib 8 , β-Ala 35 )hGLP-1 (7-36)NH 2 The title compound was synthesized substantially according to the procedure described for Example 1 using the appropriate protected amino acids. MS (ES) gave the molecular weight at 3325.7, calculated MW = 3325.8, purity = 99%, yield = 85 mg. The synthesis of other compounds of the present invention can be accomplished in substantially the same manner as the procedure described for the synthesis of (Aib 8 ' 35 )hGLP-1(7-36)NH 2 in Example 1 above, but using the appropriate protected amino acids depending on the desired peptide. Example 5 (Aib 835 , Arg 2634 , Lys 36 (N ε -tetradecanoyl))hGLP-1 (7-36)NH 2 The Boc amino acids used were the same as those in the synthesis of (Aib 8 ' 35 )hGLP-1(7-36)NH 2 described in Example 1 except that Fmoc-Lys(Boc)-OH was used in this example. The first amino acid residue was coupled to the resin manually on a shaker. 2.5 mmol of Fmoc-Lys(Boc)-OH was dissolved in 4 mL of 0.5N HBTU in DMF. To the solution was added 1 mL of DIEA. The mixture was shaken for about 2 min. To the solution was then added 0.2 mmol of MBHA resin (substitution = 0.91 mmol/g). The mixture was shaken for about 1 hr. The resin was washed with DMF and treated with 100% TFA for 2x2 min to remove the Boc protecting group. The resin was washed with DMF. Myristic acid (2.5 mmol) was pre-activated with HBTU (2.0 mmol) and DIEA (1.0 mL) in 4 mL of DMF for 2 min and was coupled to the Fmoc-Lys-resin. The coupling time was about 1 hr. The resin was washed with DMF and treated with 25% pipehdine in DMF for 2x20 min to remove the Fmoc protecting group. The resin was washed with DMF and transferred to the reaction vessel of the peptide synthesizer. The following steps synthesis and purification procedures for the peptide were the same as those in the synthesis of (Aib 8 ' 35 )hGLP-1 (7-36)NH 2 in Example 1. 43.1 mg of the title compound were obtained as a white solid. Purity was 98% based on analytical HPLC analysis. Electro-spray mass spectrometer analysis gave the molecular weight at 3577.7 in agreement with the calculated molecular weight 3578.7. Examples 6-8 Examples 6-8 were synthesized substantially according to the procedure described for Example 5 using the appropriate protected amino acid and the appropriate acid in place of the Myristic acid used in Example 5. Example 6: (Aib 835 , Arg 26 , Lys 34 (N ε -tetradecanoyl))hGLP-1 (7-36)NH 2 ; Yield = 89.6 mg; MS(ES) = 3577.2, Calculated MW = 3578.7; Purity 96%. Example 7: (Aib 835 ' 37 , Arg 2634 , Lys 38 (Nε-tetradecanoyl))hGLP-1 (7-38)NH 2 ; Yield = 63.3 mg; MS(ES) = 3818.7; Calculated MW = 3819.5; Purity 96%. Example 8: (Aib 835 , Arg 2634 , Lys 36 (Nε-decanoyl))hGLP-1 (7-36)NH 2 ; Yield = 57.4 mg; MS(ES) = 3521.5; Calculated MW = 3522.7; Purity 98%; Acid = decanoic acid. The syntheses of other compounds of the present invention containing Lys(Nε-alkanoyl) residue can be carried out in an analogous manner to the procedure described for Example 5, (Aib 8 35 , Arg 26,34 , Lys 36 (N ε -tetradecanoyl))hGLP- 1(7-36)NH 2 . Fmoc-Lys(Boc)-OH amino acid is used for the residue of Lys(N ε - alkanoyl) in the peptide, while Boc-Lys(2CIZ)-OH amino acid is used for the residue of Lys. If the Lys(Nε-alkanoyl) residue is not at the C-terminus, the peptide fragment immediately prior to the Lys(N ε -alkanoyl) residue is assembled on the resin on the peptide synthesizer first. The appropriate acid corresponding to the desired alkanoyl can be purchased from Aldrich Chemical Co., Inc. Milwaukee, Wl, USA, e.g., octanoic acid, decanoic acid, lauric acid and palmitic acid. Example 9 (Aib 8 35 , Arg 2634 , Lys 36 (N ε -dodecanesulfonyl))hGLP-1 (7-36)NH 2 The Boc amino acids to be used in this synthesis are the same as those used in the synthesis of Example 5. The first amino acid residue is coupled to the resin manually on a shaker. 2.5 mmol of Fmoc-Lys(Boc)-OH is dissolved in 4 mL of 0.5N HBTU in DMF. To the solution is added 1 mL of DIEA. The mixture is shaken for about 2 min. To the solution is then added 0.2 mmol of MBHA resin(substitution = 0.91 mmol/g). The mixture is shaken for about 1 hr. The resin is washed with DMF and treated with 100% TFA for 2x2 min to remove the Boc protecting group. The resin is washed with DMF and to it is added 0.25 mmol of 1-dodecanesulfonyl chloride in 4 mL of DMF and 1 mL of DIEA. The mixture is shaken for about 2 hrs. The resin is washed with DMF and treated with 25% piperidine in DMF for 2 x 20 min to remove the Fmoc protecting group. The resin is washed with DMF and transferred to the reaction vessel of the peptide synthesizer. The synthesis of the rest of the peptide and purification procedures are the same as those described in Example 1. The syntheses of other compounds of the present invention containing Lys(Nε-alkylsulfonyl) residue can be carried out in an analogous manner to the procedure described in Example 9. Fmoc-Lys(Boc)-OH amino acid is used for the residue of Lys(Nε-alkylsulfonyl) in the peptide, while Boc-Lys(2CIZ)-OH amino acid is used for the residue of Lys. If the Lys(N ε -alkylsulfonyl) residue is not at the C- terminus, the peptide fragment immediately prior to the Lys(N ε -alkylsulfonyl) residue is assembled on the resin on the peptide synthesizer first. The appropriate akylsulfonyl chloride can be obtained from Lancaster Synthesis Inc., Windham, NH, USA, e.g., 1-octanesulfonyl chloride, 1-decanesulfonyl chloride, 1- dodecanesulfonyl chloride, 1-hexadecanesulfonyl chloride and 1-octadecylsulfonyl chloride. Example 10 (Aib 835 , Arg 2634 , Lys 36 (Nε-(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1 (7-36)NH 2 The Boc amino acids to be used for this example are the same as those used in the synthesis of Example 5. The first amino acid residue is coupled to the resin manually on a shaker. 2.5 mmol of Fmoc-Lys(Boc)-OH is dissolved in 4 mL of 0.5N HBTU in DMF. To the solution is added 1 mL of DIEA. The mixture is shaken for about 2 min. To the solution is then added 0.2 mmol of MBHA (substitution = 0.91 mmol/g) resin. The mixture is shaken for about 1 hr. The resin is washed with DMF and treated with 100% TFA for 2x2 min to remove the Boc protecting group. The resin is washed with DMF. The 2-bromoacetic acid (2.5 mmol) is pre-activated with HBTU (2.0 mmol) and DIEA (1 mL) in 4 mL of DMF for about 2 min and is added to the resin. The mixture is shaken for about 10 min and washed with DMF. The resin is then treated with 1.2 mmol of piperazine in 4 mL of DMF for about 2 hrs. The resin is washed with DMF and treated with 2 mmol of 1 -iodotetradecane for about 4 hrs. After washing with DMF, the resin is treated with 3 mmol of acetic anhydride and 1 mL of DIEA in 4 mL of DMF for about 0.5 hr. The resin is washed with DMF and treated with 25% piperidine in DMF for 2x20 min. The resin is washed with DMF and transferred to the reaction vessel of the peptide synthesizer to continue the synthesis. The remaining synthesis and purification procedures for the peptide are the same as the procedures described for Example 1. The syntheses of other compounds of the present invention containing Lys(Nε-(2-(4-alkyl-1-piperazine)-acetyl)) residue are carried out in an analogous manner as the procedure described for the synthesis of Example 10. Fmoc- Lys(Boc)-OH amino acid is used for the residue of Lys(Nε-(2-(4-alkyl-1-piperazine)- acetyl)) in the peptide, while Boc-Lys(2CIZ)-OH amino acid is used for the residue of Lys. The corresponding iodoalkane is used for the residue of Lys(Nε-(2-(4-alkyl- 1-piperazine)-acetyl)) during the alkylation step. If the Lys(Nε-(2-(4-alkyl-1- piperazine)-acetyl)) residue is not at the C-terminus, the peptide fragment immediately prior to the Lys(N ε -(2-(4-alkyl-1-piperazine)-acetyl)) residue is assembled on the resin on the peptide synthesizer first. Example 11 (Aib 835 , Arg 2634 , Asp 36 (1-(4-tetradecyl-piperazine)))hGLP-1 (7-36)NH 2 The Boc amino acids to be used in this example are the same as the amino acids used in synthesis of Example 5 except Fmoc-Asp(O-tBu)-OH is used at position 36. The first amino acid residue is coupled to the resin manually on a shaker. 2.5 mmol of Fmoc-Asp(O-tBu)-OH is dissolved in 4 mL of 0.5N HBTU in DMF. To the solution is added 1 mL of DIEA. The mixture is shaken for about 2 min. To the solution is then added 0.2 mmol of MBHA (substitution = 0.91 mmol/g) resin. The mixture is shaken for about 1 hr. The resin is washed with DMF and treated with 100% TFA for 2x15 min to remove the tBu protecting group. The resin is washed with DMF and is treated with HBTU (0.6 mmol) and DIEA (1 mL) in 4 mL of DMF for about 15 min. 0.6 mmol of piperazine is added to the reaction mixture and the mixture is shaken for about 1 hr. The resin is washed with DMF and treated with 3 mmol of 1-iodotetradecane for about 4 hrs. After washing with DMF, the resin is treated with 3 mmol of acetic anhydride and 1 mL of DIEA in 4 mL of DMF for about 0.5 hr. The resin is washed with DMF and treated with 25% piperidine in DMF for 2x20 min to remove the Fmoc protecting group. The resin is washed with DMF and transferred to the reaction vessel of the peptide synthesizer to continue the synthesis. The remaining synthesis and purification procedures for the peptide are the same as those for the synthesis of Example 1. The syntheses of other compounds of the present invention comprising Asp(1-(4-alkylpiperazine)) or Glu(1-(4-alkylpiperazine)) residue are carried out in an analogous manner as the procedure described for the synthesis of Example 11. Fmoc-Asp(O-tBu)-OH or Fmoc-Glu(O-tBu)-OH amino acid is used for the residue of Asp(1-(4-alkylpiperazine)) or Glu(1-(4-alkylpiperazine)) in the peptide, while Boc- Asp(OcHex)-OH or Boc-Glu(OcHex)-OH amino acid is used for the residue of Asp or Glu. The corresponding iodoalkane is used for the residue of Lys(N ε -(2-(4-alkyl- 1-piperazine)-acetyl)) during the alkylation step. If the Asp(1-(4-alkylpiperazine)) or Glu(1-(4-alkylpiperazine)) residue is not at the C-terminus, the peptide fragment immediately prior to the Asp(1-(4-alkylpiperazine)) or Glu(1-(4-alkylpiperazine)) residue is assembled on the resin on the peptide synthesizer first. Example 12 (Aib 835 , Arg 2634 , Asp 36 (1-tetradecylamino))hGLP-1 (7-36)NH 2 The Boc amino acids to be used for this example are the same as those used in Example 5. The first amino acid residue is coupled to the resin manually on a shaker. 2.5 mmol of Fmoc-Asp(O-tBu)-OH is dissolved in 4 mL of 0.5N HBTU in DMF. To the solution is added 1 mL of DIEA. The mixture is shaken for about 2 min. To the solution is then added 0.2 mmol of MBHA (substitution = 0.91 mmol/g) resin. The mixture is shaken for about 1 hr. The resin is washed with DMF and treated with 100% TFA for 2x15 min to remove the t-Bu protecting group. The resin is washed with DMF and is treated with HBTU (0.6 mmol) and DIEA (1 mL) in 4 mL of DMF for about 15 min. 0.6 mmol of 1-tetradecaneamine is added to the reaction mixture and the mixture is shaken for about 1 hr. The resin is washed with DMF and treated with 25% piperidine in DMF for 2x20 min to remove the Fmoc protecting group. The resin is washed with DMF and transferred to the reaction vessel of the peptide synthesizer to continue the synthesis. The remaining synthesis and purification procedures for the peptide of this example are the same as those described for the synthesis of Example 1. The syntheses of other compounds of the present invention containing Asp(l-alkylamino) or Glu(l-alkylamino) residue are carried out in an analogous manner as described for the synthesis of Example 12. Fmoc-Asp(O-tBu)-OH or Fmoc-Glu(O-tBu)-OH amino acid is used for the residue of Asp(l-alkylamino) or Glu(l-alkylamino), respectively, in the peptide, while Boc-Asp(OcHex)-OH or Boc- Glu(OcHex)-OH amino acid is used for the residue of Asp or Glu, respectively. If the Asp(l-alkylamino) or Glu(l-alkylamino) residue is not at the C-terminus, the peptide fragment immediately prior to the Asp(l-alkylamino) or Glu(l-alkylamino) residue is assembled on the resin on the peptide synthesizer first. Example 13 (Aib 835 , Arg 2634 , Lys 36 (Nε-tetradecanoyl),β-Ala 37 )hGLP-1 (7-37)-OH The Boc amino acids used are the same as those in the synthesis of (Aib 835 , Arg 2634 , Lys 36 (Nε-tetradecanoyl))hGLP-1 (7-36)NH 2 (Example 5). 270 mg of Boc-β-Ala-PAM resin (Novabiochem, San Diego, California, substitution^.74 mmol/g) was used. The Boc protecting group on Boc-β-Ala-PAM resin was deblocked on a shaker with 100%TFA for 2x2 min first. The remainder of the synthesis and purification procedures were the same as that in Example 5. 83.0 mg of the title peptide was obtained as white solid. Purity was 99% based on analytical HPLC analysis. Electro-spray mass spectrometer analysis gave the molecular weight at 3650.5 in agreement with the calculated weight 3650.8. Example 14 (Aib 835 , Arg 2634 , Lys 36 (N ε -tetradecanoyl))hGLP-1 (7-36)-OH The Boc amino acids to be used are the same as those in the synthesis of (Aib 835 , Arg 2634 , Lys 36 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 (Example 5). Fmoc- Lys(Boc)-OH (2.5 mmol) is pre-activated with HBTU (2.0 mmol), HOBt (2.0 mmol and DIEA (2.5 ml) in DMF (4 ml) for about 2 min. This amino acid is coupled to 235 mg of PAM resin (Chem-lmpex, Wood Dale, IL; substitution = 0.85 mmol/g) manually on a shaker. The coupling time is about 8 hrs. The remainder of the synthesis and purification procedures are the same as those in Example 5. Electro-spray mass spectrometer analysis gave the molecular weight at 3579.15 in agreement with the calculated weight 3579.5. The syntheses of other analogs of hGLP-1 (7-36)-OH, hGLP-1 (7-37)-OH and hGLP-1 (7-38)-OH of the instant invention which contain Lys(Nε-alkanoyl) residue can be carried out in an analogous manner according to the procedure described for the synthesis of Example 14. Fmoc-Lys(Boc)-OH amino acid is used for the residue of Lys(Nε-alkanoyl) in the peptide, while Boc-Lys(2CIZ)-OH amino acid is used for the residue of Lys. Example 366 (Aib 8 , β-Ala 35 , Aec 37 )hGLP-1(7-37)NH 2 A mixture of MBHA resin (0.2mmol, substitution^.91 mmol/g), Fmoc-Aec- OH (0.40g, 0.829 mmol), HBTU (1.5 mL @ 0.5M in DMF) and DIEA (0.5mL) in a reaction vessel was shaken on a shaker for 4h at room temperature. The resin was then washed with DMF and treated with 25% piperidine in DMF for 2X20min. The resin was washed with DMF and DCM and transferred to the reaction vessel of the peptide synthesizer to continue the assembly of the rest of the peptide according the procedure described for Example 1. The purification procedure was also the same as the one described in Example 1. Electro-spry mass spectrometer analysis gave the molecular weight at 3494.8 in agreement with the calculated molecular weight 3494.99. Purity 93%; Yield 79.1mg. Example 367 (Aib 8 , β-Ala 35 , Aec 38 )hGLP-1 (7-38)NH 2 Example 367 was synthesized substantially according to the procedure described for Example 366. MS(ES)=3551.7, calculated MW=3552.04; Purity 97%; Yield 97.4mg. Example 368: (Aib 8 , β-Ala 35 , Aec 37 ' 38 )hGLP-1 (7-38)NH 2 A mixture of MBHA resin (0.2mmol, substitution^.91 mmol/g), Fmoc-Aec- OH (0.289g, 0.6 mmol), HBTU (1.12 mL @ 0.5M in DMF) and DIEA (0.4mL) in a reaction vessel was shaken on a shaker for 2h at room temperature. The resin was then washed with DMF and treated with 30% piperidine in DMF for 2X15min. The resin was washed with DMF. To the reaction vessel were added Fmoc-Aec-OH (0.289g, 0.6 mmol), HBTU (1.12 mL @ 0.5M in DMF) and DIEA (0.4mL). The mixture was shaken at room temperature for 2h. The resin was washed with DMF and treated with 30% piperidine in DMF for 2X15min. The resin was washed with DMF and DCM and transferred to the reaction vessel of the peptide synthesizer to continue the assembly of the rest of the peptide according the procedure described for Example 1. The purification procedure was also the same as the one described in Example 1. Electro-spry mass spectrometer analysis gave the molecular weight at 3663.9 in agreement with the calculated molecular weight 3664.26. Purity 100%; Yield 75.3mg. Example 369 (Aib 8 , Arg 26 ' 34 , β-Ala 35 , Lys 36 (N ε -Aec-decanoyl))hGLP-1 (7-36)NH 2 A mixture of MBHA resin (0.2mmol, substitution^.91 mmol/g), Boc- Lys(Fmoc)-OH (1.17g, 2.5mmol), HBTU (4 mL @ 0.5M in DMF) and DIEA (1 mL) in a reaction vessel was shaken on a shaker at room temperature for 10min. The resin was washed with DMF and treated with 25% piperidine in DMF for 2X15min. The resin was washed with DMF. To the reaction vessel were added Fmoc-Aec-OH (0.289g, 0.6 mmol), HBTU (1.12 mL @ 0.5M in DMF) and DIEA (0.4mL). The mixture was shaken at room temperature for 10min. The resin was washed with DMF and treated with 30% piperidine in DMF for 2X15min. The resin was washed with DMF and treated with a mixture of decanoic acid (431 mg, 2.5 mmol), HBTU (4 mL @ 0.5M in DMF) and DIEA (1mL) for 10 min. The resin was washed with DMF and treated with 100% TFA for 2X2 min. The resin was washed with DMF and DCM and transferred to the reaction vessel of the peptide synthesizer to continue the assembly of the rest of the peptide according the procedure described for Example 1. The purification procedure was also the same as the one described in Example 1. Electro-spry mass spectrometer analysis gave the molecular weight at 3677.0 in agreement with the calculated molecular weight 3677.25. Purity 97.6%;Yield 44.8mg. The following examples can be made according to the appropriate procedures described hereinabove. Example 15 (Aib 35 )hGLP-1 (7-36)NH 2 Example 16: (β-Ala 35 )hGLP-1 (7-36)NH 2 exempt ((N « -Me-His) 7 , Aib 8 ' 35 )hGLP-1 (7-36)NH 2 Example is ((N α -Me-His) 7 , Aib 8 , β-Ala 35 )hGLP-1 (7-36)NH 2 E a mpl e i9 ((N"-Me-His) 7 , Aib 8 ' 35 , Arg 26 ' 34 )hGLP-1 (7-36)NH 2 Example 20: ((N α -Me-His) 7 , Aib 8 , Arg 26 ' 34 , β-Ala 35 )hGLP-1 (7-36)NH 2 E χa p,e 2 i (Aib 8 , A6c 35 )hGLP-1 (7-36)NH 2 Exam pl e s (Aib 8 , A5c 35 )hGLP-1 (7-36)NH 2 Example 23: (Aib 8 , D-Ala 35 )hGLP-1(7-36)NH 2 Example 24: (Aib 835 , A6c 32 )hGLP-1 (7-36)NH 2 Example 25: (Aib 835 , A5c 32 )hGLP-1(7-36)NH 2 Example 26: (Aib 835 , Glu 23 )hGLP-1 (7-36)NH 2 E xam pl e 27 (Aib 8 ' 24 ' 35 )hGLP-1 (7-36)NH 2 E amp l e 28 (Aib 8 ' 30 ' 35 )hGLP-1 (7-36)NH 2 Exampl e 29 (Aib 8 ' 25 ' 35 )hGLP-1 (7-36)NH 2 Example 30: (Aib 835 , A6c 16 ' 20 )hGLP-1 (7-36)NH 2 Example 31 : (Aib 835 , A6c 16 ' 29 ' 32 )hGLP-1 (7-36)NH 2 Example 32: (Aib 835 , A6c 20 ' 3 )hGLP-1 (7-36)NH 2 Example 33: (Aib 835 , A6c 20 )hGLP-1(7-36)NH 2 Example 34: (Aib 835 , Lys 25 )hGLP-1 (7-36)NH 2 Example 35: (Aib 82435 , A6c 20 )hGLP-1 (7-36)NH 2 Example 36: (Aib 835 , A6c 29 ' 32 )hGLP-1(7-36)NH 2 E amp l e s (Aib 8 24 35 , A6c 29 ' 32 )hGLP-1 (7-36)NH 2 Example 38: (Aib 835 , A6c 12 )hGLP-1(7-36)NH 2 Example 39: (Aib 835 , Cha 20 )hGLP-1(7-36)NH 2 E xamp l e (Aib 8 35 , A6c 33 )hGLP-1 (7-36)NH 2 exam pl e 4 ι (Aib 8 35 , A6c 20 ' 32 )hGLP-1 (7-36)NH 2 Exam pl es (Aib 8 , A6c 16 ' 20 , β-Ala 35 )hGLP-1 (7-36)NH 2 Example 43: (Aib 835 , β-Ala 22 )hGLP-1 (7-36)NH 2 Example 44 (Aib 8 ' 2235 )hGLP-1 (7-36)NH 2 Example 45: (Aib 835 , Glu 23 , A6c 32 )hGLP-1(7-36)NH 2 E xam p ie 46 (Aib 8 24 35 , Glu 23 , A6c 32 )hGLP-1 (7-36)NH 2 E xam p ie. 7 (Aib 8 24 ' 25 ' 35 , Glu 23 , A6c 32 )hGLP-1 (7-36)NH 2 E xam P ie 48 (Aib 8 ' 24 ' 25 35 , A6c 16 ' 20 ' 32 , Glu 23 )hGLP-1 (7-36)NH 2 Example 49: (Aib 8 , A6c 32 , β-Ala 35 )hGLP-1 (7-36)NH 2 Example 50: (Aib 8 , A5c 32 , β-Ala 35 )hGLP-1(7-36)NH 2 Example 51 : (Aib 8 , Glu 23 , β-Ala 35 )hGLP-1 (7-36)NH 2 E xam pl e 52 (Aib 8 24 , β-Ala 35 )hGLP-1 (7-36)NH 2 Example 53 (Aib 8 30 , β-Ala 35 )hGLP-1 (7-36)NH 2 xam P ,e 5 4 (Aib 8 25 , β-Ala 35 )hGLP-1 (7-36)NH 2 Example 55: (Aib 8 , A6c 16 ' 20 , β-Ala 35 )hGLP-1 (7-36)NH 2 Example 56: (Aib 8 , A6c 16 ' 2932 , β-Ala 35 )hGLP-1 (7-36)NH 2 Example 57: (Aib 8 , A6c 20 ' 32 , β-Ala 35 )hGLP-1 (7-36)NH 2 Example 58: (Aib 8 , A6c 20 , β-Ala 35 )hGLP-1 (7-36)NH 2 Example 59: (Aib 8 , Lys 25 , β-Ala 35 )hGLP-1 (7-36)NH 2 Example 60: (Aib 824 , A6c 20 , β-Ala 35 )hGLP-1(7-36)NH 2 Example 61 : (Aib 8 , A6c 2932 , β -Ala 35 )hGLP-1 (7-36)NH 2 Exa pl e 62 (Aib 8 24 , A6c 29 32 , β-Ala 35 )hGLP-1 (7-36)NH 2 Example 63: (Aib 8 , A6c 12 , β-Ala 35 )hGLP-1 (7-36)NH 2 Example 64: (Aib 8 , Cha 20 , β-Ala 35 )hGLP-1 (7-36)NH 2 Exam pl e 6 5 (Aib 8 , A6c 33 , β-Ala 35 )hGLP-1 (7-36)NH 2 xam pl e 66 (Aib 8 , A6c 20 ' 32 , β-Ala 35 )hGLP-1 (7-36)NH 2 Example 67: (Aib 8 , β-Ala 2235 )hGLP-1(7-36)NH 2 Exam pl e 68 (Aib 8 22 , β-Ala 35 )hGLP-1 (7-36)NH 2 Example 69: (Aib 8 , Glu 23 , A6c 32 , β-Ala 35 )hGLP-1(7-36)NH 2 xam pl e 70 (Aib 8 24 , Glu 23 , A6c 32 , β-Ala 35 )hGLP-1 (7-36)NH 2 Exam pl e (Aib 8 24 , Glu 23 , A6c 32 , Lys 34 (N ε -octanoyl), β-Ala 35 )hGLP-1 (7-36)NH 2 Examp l e 2 (Aib 8 24 25 , Glu 23 , A6c 32 , β-Ala 35 )hGLP-1 (7-36)NH 2 Exam pl e 73 (Aib 8 24 25 , A6c 16 ' 20 ' 32 , Glu 23 , β-Ala 35 )hGLP-1 (7-36)NH 2 Exam pl e 74 (Aib 8 35 , D-Arg 36 )hGLP-1 (7-36)NH 2 Exam pl e 75 (Aib 8 35 , D-Lys 36 )hGLP-1 (7-36)NH 2 Exam pl e 76 (Aib 8 , β-Ala 35 , D-Arg 36 )hGLP-1 (7-36)NH 2 Exam pl e 77 (Aib 8 , β-Ala 35 , D-Lys 36 )hGLP-1 (7-36)NH 2 Example 78 (Aib 8 35 , Arg 26 ' 34 )hGLP-1 (7-36)NH 2 Exam pl e 79 (Aib 8 , Arg 26 34 , β-Ala 35 )hGLP-1 (7-36)NH 2 Examp l e 80 (Aib 8 35 , Arg 25 ' 26 ' 34 )hGLP-1 (7-36)NH 2 Exam pl e 81 (Aib 8 , Arg 25 26 34 , β-Ala 35 )hGLP-1 (7-36)NH 2 Examp , e 82 (Aib 8 , Arg 2634 , β -Ala 35 , Lys 36 (N ε -tetradecanoyl))hGLP-1 (7-36)OH Example 83 (Aib 835 , Arg 2634 , Lys 36 (N ε -tetradecanoyl))hGLP-1 (7-37)OH Example 84: (Aib 83537 , Arg 2634 , Lys 36 (N ε -tetradecanoyl))hGLP-1 (7-37)OH Example 85 (Aib 8 35 , Arg 2634 , Lys 36 (N ε -tetradecanoyl), D-Ala 37 )hGLP-1(7-37)OH Example 86: (Aib 83537 , Arg 2634 , Lys 38 (N ε -tetradecanoyl))hGLP-1 (7-38)OH Example 87: (Aib 835 , Arg 2634 , β-Ala 37 , Lys 38 (N ε -tetradecanoyl))hGLP-1 (7-38)OH Example 88: (Aib 8 ' 35 , Arg 26 ' 34 , Lys 38 (N ε -tetradecanoyl))hGLP-1 (7-38)OH Example 89 (Aib 8 , Arg 26 ' 34 , Lys 36 (N ε -tetradecanoyl), β-Ala 37 )hGLP-1 (7-37)OH Example 90: (Aib 837 , Arg 2634 , Lys 36 (N ε -tetradecanoyl))hGLP-1 (7-37)OH Example 91: (Aib 835 , Arg 2634 , Ado 37 )hGLP-1(7-37)OH Example 92: (Aib 835 , Arg 26 ' 34 , Ado 37 )hGLP-1 (7-37)NH 2 Example 93 (Aib 8 , Arg 2634 , Lys 36 (N ε -tetradecanoyl), D-Ala 37 )hGLP-1 (7-37)OH Example 94 (Aib 837 , Arg 2634 , Lys 38 (N ε -tetradecanoyl))hGLP-1(7-38)OH Example 95: (Aib 8 , Arg 26 ' 34 , β-Ala 37 , Lys 38 (N ε -tetradecanoyl))hGLP-1 (7-38)OH Example 96: (Aib 835 , Lys 26 (N ε -octanoyl))hGLP-1 (7-36)NH 2 Example 97 (Aib 835 , Lys 26 (N ε -tetradecanoyl))hGLP-1 (7-36)NH 2 Example 98: (Aib 835 , Lys 26 (N ε -hexadecanoyl))hGLP-1 (7-36)NH 2 Example 99: (Aib 8 , Lys 26 (N ε -octanoyl), β-Ala 35 )hGLP-1(7-36)NH 2 Example 100: (Aib 8 , Lys 26 (N ε -tetradecanoyl), β-Ala 35 )hGLP-1 (7-36)NH 2 Example 101 : (Aib 8 , Lys 26 (N ε -hexadecanoyl), β-Ala 35 )hGLP-1 (7-36)NH 2 Example 102: (Aib 835 , Lys 26 (N ε -octanoyl), Arg 34 )hGLP-1 (7-36)NH 2 Example 103: (Aib 835 , Lys 26 (N ε -tetradecanoyl), Arg 34 )hGLP-1 (7-36)NH 2 Example 104 (Aib 835 , Lys 26 (N ε -hexadecanoyl), Arg 34 )hGLP-1(7-36)NH 2 Example 105: (Aib 8 35 , Lys 26 (N ε -decanoyl), Arg 34 )hGLP-1 (7-36)NH 2 Example 106: (Aib 835 , Lys 25 , Lys 26 (N ε -octanoyl), Arg 34 )hGLP-1 (7-36)NH 2 Example 107: (Aib 835 , Lys 25 , Lys 26 (N ε -tetradecanoyl), Arg 34 )hGLP-1 (7-36)NH 2 Example 108 (Aib 8 35 , Lys 25 , Lys 26 (N ε -hexadecanoyl), Arg 34 )hGLP-1(7-36)NH 2 Example 109: (Aib 8 35 , Arg 25 ' 34 , Lys 26 (N ε -octanoyl))hGLP-1 (7-36)NH 2 Example 110: (Aib 8 35 , Arg 2534 , Lys 26 (N ε -tetradecanoyl))hGLP-1 (7-36)NH 2 Example in (Aib 8 35 , Arg 2534 , Lys 26 (N ε -hexadecanoyl))hGLP-1 (7-36)NH 2 Example 112 (Aib 835 , Arg 2534 , Lys 26 (N ε -decanoyl))hGLP-1 (7-36)NH 2 Example 113: (Aib 8 , Lys 26 (N ε -octanoyl), Arg 34 , β-Ala 35 )hGLP-1 (7-36)NH 2 Example 1 14: (Aib 8 , Lys 26 (N ε -tetradecanoyl), Arg 34 , β-Ala 35 )hGLP-1 (7-36)NH 2 Example us (Aib 8 , Lys 26 (N ε -hexadecanoyl), Arg 34 , β-Ala 35 )hGLP-1 (7-36)NH 2 Example 116: (Aib 8 , Lys 26 (N ε -decanoyl), Arg 34 , β-Ala 35 )hGLP-1 (7-36)NH 2 Example 1 17: (Aib 835 , Lys 34 (N ε -octanoyl))hGLP-1 (7-36)NH 2 Example 1 18: (Aib 835 , Lys 34 (N ε -tetradecanoyl))hGLP-1 (7-36)NH 2 Example 1 19: (Aib 835 , Lys 34 (N ε -hexadecanoyl))hGLP-1 (7-36)NH 2 Example 120: (Aib 8 35 , Arg 26 , Lys 34 (N ε -octanoyl))hGLP-1 (7-36)NH 2 Example 121 (Aib 8 35 , Arg 26 , Lys 34 (N ε -hexadecanoyl))hGLP-1 (7-36)NH 2 Example 122: (Aib 8 35 , Arg 26 , Lys 34 (N ε -decanoyl))hGLP-1 (7-36)NH 2 Example 123: (Aib 8 35 , Arg 2526 , Lys 34 (N ε -octanoyl))hGLP-1 (7-36)NH 2 Example 124: (Aib 8 35 , Arg 2526 , Lys 34 (N ε -tetradecanoyl))hGLP-1 (7-36)NH 2 Example 125 (Aib 8 35 , Arg 2526 , Lys 34 (N ε -hexadecanoyl))hGLP-1 (7-36)NH 2 Example 126: (Aib 8 35 , Arg 25 26 , Lys 34 (N ε -decanoyl))hGLP-1 (7-36)NH 2 Example 127: (Aib 8 35 , Lys 25 , Arg 26 , Lys 34 (N ε -octanoyl))hGLP-1 (7-36)NH 2 Example 128: (Aib 8 35 , Lys 25 , Arg 26 , Lys 34 (N ε -tetradecanoyl))hGLP-1 (7-36)NH 2 Example 129: (Aib 8 35 , Lys 25 , Arg 26 , Lys 34 (N ε -hexadecanoyl))hGLP-1 (7-36)NH 2 Example 130: (Aib 8 35 , Lys 36 (N ε -octanoyl))hGLP-1 (7-36)NH 2 Example 131 (Aib 8 35 , Lys 36 (N ε -tetradecanoyl))hGLP-1 (7-36)NH 2 Example 132: (Aib 8 35 , Lys 36 (N ε -hexadecanoyl))hGLP-1 (7-36)NH 2 Example 133: (Aib 8 35 , Arg 26 , Lys 36 (N ε -octanoyl))hGLP-1 (7-36)NH 2 Example 134: (Aib 8 35 , Arg 26 , Lys 36 (N ε -tetradecanoyl))hGLP-1 (7-36)NH 2 Example 135: (Aib 835 , Arg 26 , Lys 36 (N ε -hexadecanoyl))hGLP-1 (7-36)NH 2 Example 136: (Aib 8 ' 35 , Arg 26 ' 34 , Lys 36 (N ε -octanoyl))hGLP-1 (7-36)NH 2 Example 137 (Aib 8 35 , Arg 26 ' 34 , Lys 36 (N ε -hexadecanoyl))hGLP-1 (7-36)NH 2 Example 138 (Aib 8 35 , Arg 26 ' 34 , Ly S 38 (N ε -octanoyl))hGLP-1 (7-38)NH 2 Examp , e 139 (Aib 8 35 , Arg 26 34 , Lys 38 (N ε -decanoyl))hGLP-1 (7-38)NH 2 Example 140: (Aib 8 35 , Arg 2634 , Lys 38 (N ε -tetradecanoyl))hGLP-1 (7-38)NH 2 Example HI (Aib 8 35 , Arg 26 ' 34 , Lys 38 (N ε -hexadecanoyl))hGLP-1 (7-38)NH 2 Example 142 (Aib 8 3537 , Arg 252634 , Ly S 38 (N ε -octanoyl))hGLP-1 (7-38)NH 2 Example 143 (Aib 8 ' 3537 , Arg 2526 ' 34 , Ly S 38 (N ε -decanoyl))hGLP-1 (7-38)NH 2 Example 144: (Aib 8 ' 3537 , Arg 25 ' 26 ' 34 , Lys 38 (N ε -tetradecanoyl))hGLP-1 (7-38)NH 2 Example us (Aib 8 ' 3537 , Arg 25 ' 26 34 , Lys 38 (N ε -hexadecanoyl))hGLP-1 (7-38)NH 2 Example 146 (Aib 8 35 37 , Arg 2634 , Lys 38 (N ε -octanoyl))hGLP-1 (7-38)NH 2 ExamP , e 147 (Aib 8 3537 , Arg 26 34 , Lys 38 (N ε -decanoyl))hGLP-1 (7-38)NH 2 Example 148 (Aib 8 3537 , Arg 2634 , Lys 38 (N ε -hexadecanoyl))hGLP-1 (7-38)NH 2 Example 14β (Aib 8 35 37 , Arg 252634 , Lys 38 (N ε -octanoyl))hGLP-1 (7-38)NH 2 Example 150 (Aib 83537 , Arg 2526 ' 34 , Lys 38 (N ε -decanoyl))hGLP-1 (7-38)NH 2 Example 151 : (Aib 8 - 3537 , Arg 25 2634 , Lys 38 (N ε -tetradecanoyl))hGLP-1 (7-38)NH 2 ExamP i e i 52 (Aib 8 ' 3537 , Arg 2526 ' 34 , Ly S 38 (N ε -hexadecanoyl))hGLP-1 (7-38)NH 2 Example 153: (Aib 835 , Lys 25 , Arg 2634 , Lys 36 (N ε -octanoyl))hGLP-1 (7-36)NH 2 Example 154: (Aib 835 , Lys 25 , Arg 26 ' 34 , Lys 36 (N ε -tetradecanoyl))hGLP-1 (7-36)NH 2 Example 155: (Aib 835 , Lys 25 , Arg 26 ' 34 , Lys 36 (N ε -hexadecanoyl))hGLP-1 (7-36)NH 2 Example 156: (Aib 835 , Arg 25 ' 2634 , Lys 36 (N ε -octanoyl))hGLP-1 (7-36)NH 2 Example 157: (Aib 835 , Arg 252634 , Lys 36 (N ε -tetradecanoyl))hGLP-1 (7-36)NH 2 Ex a m p l e 1 5 8 (Aib 8 ' 35 , Arg 252634 , Lys 36 (N ε -hexadecanoyl))hGLP-1 (7-36)NH 2 Exam p le 159 (Aib 835 , Arg 252634 , Lys 36 (N ε -decanoyl))hGLP-1 (7-36)NH 2 Example 160: (Aib 8 , Lys 34 (N ε -octanoyl), β-Ala 35 )hGLP-1 (7-36)NH 2 Example 161 : (Aib 8 , Lys 34 (N ε -tetradecanoyl), β-Ala 35 )hGLP-1 (7-36)NH 2 Example 162: (Aib 8 , Lys 34 (N ε -hexadecanoyl), β-Ala 35 )hGLP-1 (7-36)NH 2 Example 163: (Aib 8 , A6c 32 , Lys 34 (Nε-octanoyl), β-Ala 35 )hGLP-1 (7-36)NH 2 Example 164: (Aib 8 , Glu 23 , Lys 34 (Nε-octanoyl), β-Ala 35 )hGLP-1 (7-36)NH 2 Example 165: (Aib 8 , Glu 23 , A6c 32 , Lys 34 (Nε-octanoyl), β-Ala 35 )hGLP-1 (7-36)NH 2 Example 166: (Aib 8 , Arg 26 , Lys 34 (N ε -octanoyl), β-Ala 35 )hGLP-1 (7-36)NH 2 Ex a m p l e 16 7 (Aib 8 , Arg 26 , Lys 34 (N ε -tetradecanoyl), β -Ala 35 )hGLP-1 (7-36)NH 2 Ex a m p l e 1 68 (Aib 8 , Arg 26 , Lys 34 (N ε -hexadecanoyl), β -Ala 35 )hGLP-1 (7-36)NH 2 Ex a m p l e 169 (Aib 8 , Arg 26 , Lys 34 (N ε -decanoyl), β -Ala 35 )hGLP-1 (7-36)NH 2 Example 170: (Aib 8 , Arg 2526 , Lys 34 (N ε -octanoyl), β -Ala 35 )hGLP-1 (7-36)NH 2 Example 171 : (Aib 8 , Arg 2526 , Lys 34 (N ε -tetradecanoyl), β-Ala 35 )hGLP-1 (7-36)NH 2 Ex a m p le 1 7 2 (Aib 8 , Arg 25 ' 26 , Lys 34 (N ε -hexadecanoyl), β-Ala 35 )hGLP-1 (7-36)NH 2 Ex a m p le 173 (Aib 8 , Arg 2526 , Lys 34 (N ε -decanoyl), β -Ala 35 )hGLP-1 (7-36)NH 2 Example 174: (Aib 8 , Lys 25 , Arg 26 , Lys 34 (N ε -octanoyl), β-Ala 35 )hGLP-1 (7-36)NH 2 Example 175: (Aib 8 , Lys 25 , Arg 26 , Lys 34 (N ε -tetradecanoyl), β-Ala 35 )hGLP-1 (7-36)NH 2 Example 176: (Aib 8 , Lys 25 , Arg 26 , Lys 34 (N ε -hexadecanoyl), β-Ala 35 )hGLP-1 (7-36)NH 2 Example 177: (Aib 8 , β -Ala 35 , Lys 36 (N ε -octanoyl))hGLP-1 (7-36)NH 2 Exam p le us (Aib 8 , β -Ala 35 , Lys 36 (N ε -tetradecanoyl))hGLP-1 (7-36)NH 2 Example 179: (Aib 8 , β-Ala 35 , Lys 36 (N ε -hexadecanoyl))hGLP-1 (7-36)NH 2 Example 180: (Aib 8 , Arg 26 , β-Ala 35 , Lys 36 (N ε -octanoyl))hGLP-1 (7-36)NH 2 Example 181 : (Aib 8 , Arg 26 , β-Ala 35 , Lys 36 (N ε -tetradecanoyl))hGLP-1 (7-36)NH 2 Example 182: (Aib 8 , Arg 26 , β-Ala 35 , Lys 36 (N ε -hexadecanoyl))hGLP-1 (7-36)NH 2 Example 183: (Aib 8 , Arg 26 ' 34 , β-Ala 35 , Lys 36 (N ε -octanoyl))hGLP-1 (7-36)NH 2 Example 184: (Aib 8 , Arg 2634 , β-Ala 35 , Lys 36 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 Exam p le 185 (Aib 8 , Arg 2634 , β-Ala 35 , Lys 36 (N ε - hexadecanoyl))hGLP-1(7-36)NH 2 Exam p le 18 6 (Aib 8 , Arg 2634 , β-Ala 35 , Lys 36 (N ε -decanoyl))hGLP-1(7-36)NH 2 Example 187: (Aib 8 , Lys 25 , Arg 2634 , β-Ala 35 , Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 Example 188: (Aib 8 , Lys 25 , Arg 26 ' 34 , Lys 36 (N ε -tetradecanoyl), β-Ala 35 )hGLP-1(7- 36)NH 2 Exam p le 189 (Aib 8 , Lys 25 , Arg 2634 , β-Ala 35 , Lys 36 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 Example 190: (Aib 8 , Arg 25 ' 2634 , β-Ala 35 , Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 Example 191: (Aib 8 , Arg 25 6 - 34 , β-Ala 35 , Lys 36 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 Exam p le 192 (Aib 8 , Arg 252634 , β-Ala 35 , Lys 36 (N ε -hexadecanoyl))hGLP-1 (7-36)NH 2 Example 193 (Aib 8 , Arg 252634 , β-Ala 35 , Lys 36 (N ε -decanoyl))hGLP-1 (7-36)NH 2 Example 194: (Aib 835 , Lys 26 (N ε -octanoyl), A6c 32 , Arg 34 )hGLP-1(7-36)NH 2 Exam p le 195 (Aib 835 , Lys 2S (N ε -tetradecanoyl), A6c 32 , Arg 34 )hGLP-1(7-36)NH 2 Example 196: (Aib 835 , Lys 6 (N ε -hexadecanoyl), A6c 32 , Arg 34 )hGLP-1(7-36)NH 2 Example 197: (Aib 835 , A6c 32 , Lys 34 (N ε -octanoyl))hGLP-1 (7-36)NH 2 Example 198: (Aib 835 , A6c 32 , Lys 34 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 Example 199: (Aib 835 , A6c 32 , Lys 34 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 Example 200: (Aib 835 , Arg 26 , A6c 32 , Lys 34 (N ε -octanoyl))hGLP-1(7-36)NH 2 Example 201: (Aib 835 , Arg 26 , A6c 32 , Lys 34 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 Example 202: (Aib 835 , A6c 32 , Lys 36 (N ε -octanoyl))hGLP-1 (7-36)NH 2 Example 203 (Aib 835 , A6c 32 , Lys 36 (N ε -tetradecanoyl))hGLP-1 (7-36)NH 2 Example 204: (Aib 835 , A6c 32 , Lys 36 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 Example 205: (Aib 835 , Arg 26 , A6c 32 , Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 Example 206: (Aib 835 , Arg 26 , A6c 32 , Lys 36 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 Example 207: (Aib 835 , Arg 26 , A6c 32 , Lys 36 (N ε -hexadecanoyl))hGLP-1 (7-36)NH 2 Exa m ple 208 (Aib 835 , Arg 2634 , A6c 32 , Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 Example 209: (Aib 835 , Arg 26 ' 34 , A6c 32 , Lys 36 (N ε -decanoyl))hGLP-1(7-36)NH 2 Example 210: (Aib 835 , Arg 2634 , A6c 32 , Lys 36 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 Example 211: (Aib 835 , Arg 26 ' 34 , A6c 32 , Lys 36 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 Example 212: (Aib 8 - 24 - 35 , Lys 26 (N ε -octanoyl), Arg 34 )hGLP-1 (7-36)NH 2 Example 213 (Aib 82435 , Lys 26 (N ε -tetradecanoyl), Arg 34 )hGLP-1(7-36)NH 2 Example 214: (Aib 8 - 24 ' 35 , Lys 26 (N ε -hexadecanoyl), Arg 34 )hGLP-1(7-36)NH 2 Example 215: (Aib 824 35 , Arg 26 , Lys 34 (N ε -octanoyl))hGLP-1 (7-36)NH 2 Example 216: (Aib 8 ' 24 ' 35 , Arg 26 , Lys 34 (N ε -tetradecanoyl))hGLP-1 (7-36)NH 2 Example 217: (Aib 824 ' 35 , Arg 26 , Lys 34 (N ε -hexadecanoyl))hGLP-1 (7-36)NH Example 218: (Aib 8 ' 24 ' 35 , Arg 2634 , Lys 36 (N ε -octanoyl))hGLP-1 (7-36)NH Example 219 (Aib 8 ' 4 " 5 , Arg 2634 , Lys 36 (N ε -tetradecanoyl))hGLP-1 (7-36)NH 2 Example 220: (Aib 8 24 35 , Arg 2634 , Lys 36 (N ε -hexadecanoyl))hGLP-1 (7-36)NH 2 Example 221 : (Aib 8 24 ' 35 , Glu 23 , A6c 32 , Lys 34 (Nε-octanoyl))hGLP-1 (7-36)NH 2 Example 222: (Aib 835 , Glu 23 , Lys 26 (N ε -octanoyl), Arg 34 )hGLP-1 (7-36)NH 2 Example 223 (Aib 8 35 , Glu 23 , Lys 26 (N ε -tetradecanoyl), Arg 34 )hGLP-1 (7-36)NH 2 Example 224: (Aib 8 35 , Glu 23 , Lys 26 (N ε -hexadecanoyl), Arg 34 )hGLP-1 (7-36)NH 2 Example 225: (Aib 8 35 , Glu 23 , Lys 34 (Nε-octanoyl))hGLP-1 (7-36)NH 2 Example 226: (Aib 8 ' 35 , Glu 23 , A6c 32 , Lys 34 (Nε-octanoyl))hGLP-1 (7-36)NH 2 Example 227: (Aib 835 , Glu 23 , Arg 26 , Lys 34 (N ε -octanoyl))hGLP-1 (7-36)NH 2 Example 228: (Aib 835 , Glu 23 , Arg 26 , Lys 34 (N ε -tetradecanoyl))hGLP-1 (7-36)NH 2 Example 229: (Aib 835 , Glu 23 , Arg 26 , Lys 34 (N ε -hexadecanoyl))hGLP-1 (7-36)NH 2 Example 230: (Aib 835 , Glu 23 , Lys 36 (N ε -octanoyl))hGLP-1 (7-36)NH 2 ExamP , e 23 i (Aib 835 , Glu 23 , Lys 36 (N ε -tetradecanoyl))hGLP-1 (7-36)NH 2 Example 232 (Aib 8 35 , Glu 23 , Lys 36 (N ε -hexadecanoyl))hGLP-1 (7-36)NH 2 Example 233: (Aib 835 , Glu 23 , Arg 2634 , Lys 36 (N ε -octanoyl))hGLP-1 (7-36)NH 2 e xa m ple 234 (Aib 8 35 , Glu 23 , Arg 26 ' 34 , Lys 36 (N ε -tetradecanoyl))hGLP-1 (7-36)NH 2 Example 235: (Aib 8 35 , Glu 23 , Arg 26 34 , Lys 36 (N ε -hexadecanoyl))hGLP-1 (7-36)NH 2 Example 236: (Aib 8 ' 30 35 , Lys 26 (N ε -octanoyl), Arg 34 )hGLP-1 (7-36)NH 2 Exa m ple 237 (Aib 8 30 35 , Lys 26 (N ε -tetradecanoyl), Arg 34 )hGLP-1 (7-36)NH 2 Example 238: (Aib 8 ' 3035 , Lys 26 (N ε -hexadecanoyl), Arg 34 )hGLP-1 (7-36)NH 2 Example 239: (Aib 8 ' 30 ' 35 , Arg 26 , Lys 34 (N ε -octanoyl))hGLP-1 (7-36)NH 2 Example 240: (Aib 8 ' 30 ' 35 , Arg 26 , Lys 34 (N ε -tetradecanoyl))hGLP-1 (7-36)NH 2 Example 241 : (Aib 8 ' 30 ' 35 , Arg 26 , Lys 34 (N ε -hexadecanoyl))hGLP-1 (7-36)NH 2 Example 242: (Aib 8 ' 30 ' 35 , Arg 2634 , Lys 36 (N ε -octanoyl))hGLP-1 (7-36)NH 2 Example 243 (Aib 8 30 35 , Arg 2634 , Lys 36 (N ε -tetradecanoyl))hGLP-1 (7-36)NH 2 Example 244: (Aib 8 ' 30 ' 35 , Arg 2634 , Lys 36 (N ε -hexadecanoyl))hGLP-1 (7-36)NH 2 Example 245: (Aib 8 35 , Glu 23 , A6c 32 , Lys 36 (N ε -octanoyl))hGLP-1 (7-36)NH 2 Example 246 (Aib 8 35 , Glu 23 , A6c 32 , Lys 36 (N ε -tetradecanoyl))hGLP-1 (7-36)NH 2 ExamP i e 24 (Aib 8 35 , Glu 23 , A6c 32 , Lys 36 (N ε -hexadecanoyl))hGLP-1 (7-36)NH 2 Example 248: (Aib 8 35 , Glu 23 , Arg 2634 , A6c 32 , Lys 36 (N ε -octanoyl))hGLP-1 (7-36)NH 2 Example 249 (Aib 835 , Glu 23 , Arg 26 34 , A6c 32 , Lys 36 (N ε -tetradecanoyl))hGLP-1 (7-36)NH 2 Example 250: (Aib 835 , Glu 23 , Arg 2634 , A6c 32 , Lys 36 (N ε -hexadecanoyl))hGLP-1 (7- 36)NH 2 Example 251 : (Aib 8 ' 2435 , Glu 23 , Arg 26 34 , A6c 32 , Lys 36 (N ε -octanoyl))hGLP-1 (7-36)NH 2 Example 252 (Aib 8 - 24 35 , Glu 23 , Arg 2634 , A6c 32 , Lys 36 (N ε -tetradecanoyl))hGLP-1 (7-36)NH 2 Example 253: (Aib 8 24 - 35 , Glu 23 , Arg 2634 , A6c 32 , Lys 36 (N ε -hexadecanoyl))hGLP-1 (7- 36)NH 2 Example 254: (Aib 8 ' 24 ' 3035 , Glu 23 , Arg 2634 , A6c 32 , Lys 36 (N ε -octanoyl))hGLP-1 (7-36)NH 2 Example 255 (Aib 8 2430 ' 35 , Glu 23 , Arg 26 ' 34 , A6c 32 , Lys 36 (N ε -tetradecanoyl))hGLP-1 (7-36)NH 2 Example 256: (Aib 8 ' 243035 , Glu 23 , Arg 2634 , A6c 32 , Lys 36 (N ε -hexadecanoyl))hGLP-1 (7- 36)NH 2 Example 257 ((N α -HEPES-His) 7 , Aib 35 )hGLP-1 (7-36)NH 2 Example 258 ((N α -HEPES-His) 7 , β-Ala 35 )hGLP-1 (7-36)NH 2 Example 2 59 ((N*-HEPES-His) 7 , Aib 8 , β-Ala 35 )hGLP-1 (7-36)NH 2 Example 260 ((N α -HEPA-His) 7 , Aib 35 )hGLP-1 (7-36)NH 2 E am P ,e 2 6i ((N«-HEPA-His) 7 , β-Ala 35 )hGLP-1 (7-36)NH 2 Example 2 62 ((N°-HEPA-His) 7 , Aib 8 , β-Ala 35 )hGLP-1 (7-36)NH 2 Example 263 ((N α -tetradecanoyl-His) 7 , Aib 35 )hGLP-1 (7-36)NH 2 E χ amP i e 264 ((N α -tetradecanoyl-His) 7 , β-Aia 35 )hGLP-1 (7-36)NH 2 Example 265: ((N α -tetradecanoyl-His) 7 , Aib 8 ' 35 )hGLP-1 (7-36)NH 2 Example 266: ((N α -tetradecanoyl-His) 7 , Aib 8 , β-Ala 35 )hGLP-1 (7-36)NH 2 Example 267 ((N α -tetradecanoyl-His) 7 , Arg 2634 , Aib 35 )hGLP-1 (7-36)NH 2 Example 268 ((N α -tetradecanoyl-His) 7 , Arg 2634 , β-Ala 35 )hGLP-1 (7-36)NH 2 Example 269: ((N α -tetradecanoyl-His) 7 , Aib 835 , Arg 2634 )hGLP-1 (7-36)NH 2 Example 270: ((N α -tetradecanoyl-His) 7 , Aib 8 , Arg 26 34 , β-Ala 35 )hGLP-1 (7-36)NH 2 Example 2 1 ((N α -tetradecanoyl-His) 7 , Arg 2526 34 , β-Ala 35 )hGLP-1 (7-36)NH 2 Example 272: ((N α -tetradecanoyl-His) 7 , Aib 835 , Arg 25 26 ' 34 )hGLP-1 (7-36)NH 2 Example 273: ((N α -tetradecanoyl-His) 7 , Aib 8 , Arg 25 26 ' 34 , β-Ala 35 )hGLP-1 (7-36)NH 2 Example 274: (Aib 8 35 , Lys 26 (N ε -octanesulfonyl), Arg 34 )hGLP-1 (7-36)NH 2 Example 275 (Aib 8 35 , Lys 26 (N ε -dodecanesulfonyl), Arg 34 )hGLP-1 (7-36)NH 2 Example 276: (Aib 8 35 , Lys 26 (N ε -hexadecanesulfonyl), Arg 34 )hGLP-1 (7-36)NH 2 Example 277: (Aib 835 , Arg 26 , Lys 34 (N ε -octanesulfonyl))hGLP-1 (7-36)NH 2 Exa m ple 278 (Aib 835 , Arg 26 , Lys 34 (N ε -dodecanesulfonyl))hGLP-1 (7-36)NH 2 Example 279: (Aib 8 35 , Arg 26 , Lys 34 (N ε -hexadecanesulfonyl))hGLP-1 (7-36)NH 2 Example 280: (Aib 8 35 , Arg 26 ' 34 , Lys 36 (N ε -octanesulfonyl))hGLP-1 (7-36)NH 2 Example 281 : (Aib 8 35 , Arg 2634 , Lys 36 (N ε -hexadecanesulfonyl))hGLP-1 (7-36)NH 2 ExamP , e 282 (Aib 8 35 , Asp 26 (1-(4-decylpi P erazine)), Arg 34 )hGLP-1 (7-36)NH 2 Example 283 (Aib 8 35 , Asp 26 (1-(4-dodecylpiperazine)), Arg 34 )hGLP-1 (7-36)NH 2 Example 284: (Aib 8 35 , Asp 26 (1-(4-tetradecylpiperazine)), Arg 34 )hGLP-1 (7-36)NH 2 Example 285: (Aib 835 , Asp 26 (1-(4-hexadecylpiperazine)), Arg 34 )hGLP-1 (7-36)NH 2 Exam p le 28 6 (Aib 8 35 , Arg 26 , Asp 34 (1-(4-decylpiperazine)))hGLP-1 (7-36)NH 2 Example 287 (Aib 8 35 , Arg 26 , Asp 34 (1-(4-dodecylpiperazine)))hGLP-1 (7-36)NH 2 Example 288: (Aib 835 , Arg 26 , Asp 34 (1-(4-tetradecylpiperazine)))hGLP-1 (7-36)NH 2 Example 289: (Aib 8 35 , Arg 26 , Asp 34 (1-(4-hexadecylpiperazine)))hGLP-1 (7-36)NH 2 Example 290 (Aib 8 35 , Arg 26 34 , Asp 36 (1 -(4-decylpiperazine)))hGLP-1 (7-36)NH 2 E χ amp ι e 291 (Aib 8 35 , Arg 26 34 , Asp 36 (1 -(4-dodecylpiperazine)))hGLP-1 (7-36)NH 2 Example 292: (Aib 835 , Arg 2634 , Asp 36 (1-(4-hexadecylpiperazine)))hGLP-1 (7-36)NH 2 E χ amp i e 293 (Aib 835 , Arg 2634 , Asp 38 (1-(4-decylpiperazine)))hGLP-1 (7-38)NH 2 Example 294 (Aib 8 - 35 , Arg 2634 , Asp 38 (1 -(4-dodecylpiperazine)))hGLP-1 (7-38)NH 2 Example 295: (Aib 8 35 , Arg 2634 , Asp 38 (1 -(4-tetradecylpiperazine)))hGLP-1 (7-38)NH 2 Example 296: (Aib 8 35 , Arg 2634 , Asp 38 (1-(4-hexadecylpiperazine)))hGLP-1 (7-38)NH 2 Exa m ple ^ (Aib 835 ' 37 , Arg 2634 , Asp 38 (1 -(4-decylpiperazine)))hGLP-1 (7-38)NH 2 Example 298 (Aib 8 3537 , Arg 2634 , Asp 38 (1 -(4-dodecylpiperazine)))hGLP-1 (7-38)NH 2 Example 299: (Aib 8 ' 35 - 37 , Arg 2634 , Asp 38 (1-(4-tetradecylpiperazine)))hGLP-1 (7-38)NH 2 Example 300: (Aib 8,35 - 37 , Arg 2634 , Asp 38 (1 -(4-hexadecylpiperazine)))hGLP-1 (7- 38)NH 2 Example 3 oι (Aib 835 , Arg 2534 , Asp 26 (1-(4-decylpiperazine)))hGLP-1 (7-36)NH 2 Example 302 (Aib 8 35 , Arg 25 34 , Asp 26 (1 -(4-dodecylpiperazine)))hGLP-1 (7-36)NH 2 Example 303: (Aib 8 35 , Arg 25 34 , Asp 26 (1-(4-tetradecylpiperazine)))hGLP-1 (7-36)NH 2 Example 304: (Aib 8 35 , Arg 2534 , Asp 26 (1-(4-hexadecylpiperazine)))hGLP-1 (7-36)NH 2 Example 305 (Aib 8 ' 35 , Arg 25 26 , Asp 34 (1 -(4-decylpiperazine)))hGLP-1 (7-36)NH 2 Example 306 (Aib 8 35 , Arg 2526 , Asp 34 (1-(4-dodecylpi P erazine)))hGLP-1 (7-36)NH 2 Example 307: (Aib 8 35 , Arg 25 ' 26 , Asp 34 (1-(4-tetradecylpiperazine)))hGLP-1 (7-36)NH 2 Example 308: (Aib 8 35 , Arg 25 26 , Asp 34 (1-(4-hexadecylpiperazine)))hGLP-1 (7-36)NH 2 ExamP i e 309 (Aib 8 35 , Arg 252634 , Asp 36 (1 -(4-decylpiperazine)))hGLP-1 (7-36)NH 2 Exa m ple 3 io (Aib 8 35 , Arg 25 - 26 34 , Asp 36 (1-(4-dodecyl P i P erazine)))hGLP-1 (7-36)NH 2 Example 311 : (Aib 835 , Arg 25 - 2634 , Asp 36 (1-(4-tetradecylpiperazine)))hGLP-1 (7-36)NH 2 Example 312: (Aib 835 , Arg 25 - 26 ' 34 , Asp 36 (1-(4-hexadecylpiperazine)))hGLP-1 (7- 36)NH 2 Example 313 (Aib 835 , Arg 252634 , Asp 38 (1-(4-decylpiperazine)))hGLP-1 (7-38)NH 2 Example 314 (Aib 8 35 , Arg 25 26 34 , Asp 38 (1-(4-dodecylpiperazine)))hGLP-1 (7-38)NH 2 Example 315: (Aib 8 35 , Arg 25 ' 2634 , Asp 38 (1 -(4-tetradecylpiperazine)))hGLP-1 (7-38)NH 2 Example 316: (Aib 8 - 35 , Arg 2526 - 34 , Asp 38 (1-(4-hexadecylpiperazine)))hGLP-1 (7- 38)NH 2 Example 317 (Aib 83537 , Arg 25 ' 26 ' 34 , Asp 38 (1 -(4-decylpiperazine)))hGLP-1 (7-38)NH 2 Example sis (Aib 8 3537 , Arg 25 2634 , Asp 38 (1 -(4-dodecylpiperazine)))hGLP-1 (7-38)NH 2 Example 319: (Aib 8 - 35 - 37 , Arg 25 - 26 - 34 , Asp 38 (1-(4-tetradecylpiperazine)))hGLP-1 (7- 38)NH 2 Example 32 o (Aib 8 35 37 , Arg 25 - 26 - 34 , Asp 38 (1 -(4-hexadecylpiperazine)))hGLP-1 (7-38)NH 2 Example 321 : (Aib 835 , Arg 26 - 34 , Glu 36 (1 -dodecylamino))hGLP-1 (7-36)NH 2 Example 322: (Aib 8 35 , Glu 26 (1 -dodecylamino), Arg 34 )hGLP-1 (7-36)NH 2 Exa m ple 323 (Aib 8 35 , Arg 26 , Glu 34 (1-dodecylamino))hGLP-1 (7-36)NH 2 Example 324: (Aib 8 - 35 - 37 , Arg 26 ' 34 , Glu 38 (1 -dodecylamino))hGLP-1 (7-38)NH 2 Example 325 (Aib 8 35 , Arg 34 , Lys 26 (N ε -(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1 (7-36)NH 2 Example 326 (Aib 835 , Arg 34 , Lys 26 (N ε -(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1 (7- 36)NH 2 Example 327: (Aib 8 35 , Arg 34 , Lys 26 (N ε -(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP- 1 (7-36)NH 2 Example 328: (Aib 8 35 , Arg 34 , Lys 26 (N ε -(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP- 1 (7-36)NH 2 Example 329 (Aib 8 35 , Arg 26 , Lys 34 (N ε -(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1 (7-36)NH 2 Example 330 (Aib 8 35 , Arg 26 , Ly S 34 (N ε -(2-(4-dodecyl-1 -piperazine)-acetyl))hGLP-1 (7- 36)NH 2 Example 331 . (Aib 8 35 , Arg 26 , Lys 34 (N ε -(2-(4-tetradecyl-1 -piperazine)-acetyl)))hGLP- 1 (7-36)NH 2 Example 332 (Aib 8 35 , Arg 26 , Lys 34 (N ε -(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP- 1 (7-36)NH 2 ExamP , e 333 (Aib 8 35 , Arg 2634 , Lys 36 (N ε -(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1 (7- 36)NH 2 Example 334 (Aib 8 - 35 , Arg 2634 , Lys 36 (N ε -(2-(4-dodecyl-1 -piperazine)-acetyl)))hGLP-1 (7- 36)NH 2 Example 335: (Aib 8 - 35 , Arg 26 - 34 , Lys 36 (N ε -(2-(4-hexadecyl-1 -piperazine)- acetyl)))hGLP-1 (7-36)NH 2 Example 336 (Aib 8 - 35 , Arg 2634 , Lys 38 (N ε -(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1 (7- 38)NH 2 Example 337 (Aib 8 35 , Arg 2634 , Lys 38 (N ε -(2-(4-dodecyl-1 -piperazine)-acetyl)))hGLP-1 (7- 38)NH 2 Example 338: (Aib 835 , Arg 26 34 , Lys 38 (N ε -(2-(4-tetradecyl-1 -piperazine)- acetyl)))hGLP-1 (7-38)NH 2 Example 339: (Aib 835 , Arg 2634 , Lys 38 (N ε -(2-(4-hexadecyl-1 -piperazine)- acetyl)))hGLP-1 (7-38)NH 2 Example 340 (Aib 835 - 37 , Arg 26 - 34 , Lys 38 (N ε -(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1 (7- 38)NH 2 Example 341 (Aib 8 35 - 37 , Arg 26 - 34 , Lys 38 (N ε -(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1 (7- 38)NH 2 Example 342: (Aib 835 - 37 , Arg 26 - 34 , Lys 38 (N ε -(2-(4-tetradecyl-1-piperazine)- acetyl)))hGLP-1 (7-38)NH 2 Example 343: (Aib 8 - 35 ' 37 , Arg 2634 , Lys 38 (N ε -(2-(4-hexadecyl-1 -piperazine)- acetyl)))hGLP-1 (7-38)NH 2 Example 344 (Aib 8 35 , Arg 25 - 34 , Ly S 26 (N ε -(2-(4-decyl-1 -piperazine)-acetyl)))hGLP-1 (7- 36)NH 2 Example 345 (Aib 8 - 35 , Arg 25 34 , Lys 26 (N ε -(2-(4-dodecyl-1 -piperazine)-acetyl)))hGLP-1 (7- 36)NH 2 Example 346: (Aib 8 35 , Arg 2534 , Lys 26 (N ε -(2-(4-tetradecyl-1 -piperazine)- acetyl)))hGLP-1 (7-36)NH 2 Example 347: Aib 8 35 , Arg 25 - 34 , Lys 26 (N ε -(2-(4-hexadecyl-1 -piperazine)-acetyl)))hGLP- 1 (7-36)NH 2 Example 348 (Aib 8 35 , Arg 25 - 26 , Lys 34 (N ε -(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1 (7- 36)NH 2 E χ amP i e 349 (Aib 8 - 35 , Arg 2526 , Lys 34 (N ε -(2-(4-dodecyl-1 -piperazine)-acetyl)))hGLP-1 (7- 36)NH 2 Example 350: (Aib 8 - 35 , Arg 25 - 26 , Lys 34 (N ε -(2-(4-tetradecyl-1 -piperazine)- acetyl)))hGLP-1 (7-36)NH 2 Example 351 : (Aib 8 - 35 , Arg 2526 , Lys 34 (N ε -(2-(4-hexadecyl-1 -piperazine)- acetyl)))hGLP-1 (7-36)NH 2 Exa mp le 352 (Aib 8 - 35 , Arg 252634 , Lys 36 (N ε -(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1 (7- 36)NH 2 Example 353 (Aib 8 - 35 , Arg 25 - 2634 , Lys 36 (N ε -(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1 (7- 36)NH 2 Example 354: (Aib 8 35 , Arg 25 ' 26 - 34 , Lys 36 (N ε -(2-(4-tetradecyl-1-piperazine)- acetyl)))hGLP-1 (7-36)NH 2 Example 355: (Aib 8 - 35 , Arg 25 - 2634 , Lys 36 (N ε -(2-(4-hexadecyl-1-piperazine)- acetyl)))hGLP-1 (7-36)NH 2 Examp i e 356 (Aib 8 - 35 , Arg 252634 , Lys 38 (N ε -(2-(4-decyl-1 -piperazine)-acetyl)))hGLP-1 (7- 38)NH 2 Example 357 (Aib 8 35 , Arg 25 ' 2634 , Lys 38 (N ε -(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1 (7- 38)NH 2 Example 358: (Aib 8 35 , Arg 25 ' 26 ' 34 , Lys 38 (N ε -(2-(4-tetradecyl-1 -piperazine)- acetyl)))hGLP-1 (7-38)NH 2 Example 359: (Aib 8 - 35 , Arg 25 - 2634 , Lys 38 (N ε -(2-(4-hexadecyl-1-piperazine)- acetyl)))hGLP-1 (7-38)NH 2 Example 360 (Aib 8 - 35 - 37 , Arg 25 - 2634 , Lys 38 (N ε -(2-(4-decyl-1 -piperazine)-acetyl)))hGLP-1 (7- 38)NH 2 E χ amP i e 361 (Aib 8 3537 , Arg 25 ' 26 - 34 , Lys 38 (N ε -(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP- 1 (7-38)NH 2 Example 362: (Aib 8 - 35 37 , Arg 25 2634 , Lys 38 (N ε -(2-(4-tetradecyl-1-piperazine)- acetyl)))hGLP-1 (7-38)NH 2 Example 363 (Aib 8 35 ' 37 , Arg 25 ' 2634 , Lys 38 (N ε -(2-(4-hexadecyl-1 -piperazine)-acetyl)))hGLP- 1 (7-38)NH 2 Example 364: (Aib 8 35 , Arg 26 - 34 , Lys 36 (N ε -decanoyl))hGLP-1 (7-36)OH Example 365: (Aib 8 - 35 , Lys 25 , Arg 26 - 34 , Lys 36 (N ε -decanoyl))hGLP-1 (7-36)OH Example 370 (Aib 8 ' 35 ,Arg 26 - 34 , Ava 37 , Ado 38 )hGLP-1 (7-38)NH 2 Example 371 (Aib 835 ,Arg 26 ' 34 , Asp 37 , Ava 38 , Ado 39 )hGLP-1 (7-39)NH 2 Example 372 (Aib 8 ' 35 ,Arg 26 ' 34 , Aun 37 )hGLP-1 (7-37)NH 2 Example 373 (Aib 8 ' 17 ' 35 ,)hGLP-1 (7-36)NH 2 Example 374 (Aib 8 ,Arg 2634 , β-Ala 35 , D-Asp 37 , Ava 38 , Aun 39 )hGLP-1 (7-39)NH 2 Example 375 (Gly 8 , β-Ala 35 )hGLP-1 (7-36)NH 2 Example 376 (Ser 8 , β-Ala 35 )hGLP-1 (7-36)NH 2 Example 377 (Aib 8 , Glu 22 - 23 , β-Ala 35 )hGLP-1 (7-36)NH 2 Example 378 (Gly 8 , Aib 35 )hGLP-1 (7-36)NH 2 Example 379 (Aib 8 , Lys 18 , β-Ala 35 )hGLP-1 (7-36)NH 2 Example 380 (Aib 8 , Leu 27 , β-Ala 35 )hGLP-1 (7-36)NH 2 Example 381 (Aib 8 , Lys 33 , β-Ala 35 )hGLP-1 (7-36)NH 2 Example 382 (Aib 8 , Lys 18 , Leu 27 , β-Ala 35 )hGLP-1 (7-36)NH 2 Example 383 (Aib 8 , D-Arg 36 )hGLP-1 (7-36)NH 2 Example 384 (Aib 8 , β-Ala 35 , D-Arg 37 )hGLP-1(7-37)NH 2 Example 385 (Aib 8 - 27 , β-Ala 35 )hGLP-1(7-36)NH 2 Example 386 (Aib 827 , β-Ala 35 ' 37 , Arg 38 )hGLP-1(7-38)NH 2 Example 387 (Aib 827 , β-Ala 35 ' 37 , Arg 38 - 39 )hGLP-1 (7-39)NH 2 Example 388 (Aib 8 , Lys 1827 , β-Ala 35 )hGLP-1 (7-36)NH 2 Example 389 (Aib 8 , Lys 27 , β-Ala 35 )hGLP-1 (7-36)NH 2 Example 390 (Aib 8 , β-Ala 35 , Arg 38 )hGLP-1 (7-38)NH 2 Example 391 (Aib 8 , Arg 2634 , β-Ala 35 ,)hGLP-1 (7-36)NH 2 Example 392 (Aib 8 , D-Arg 35 )hGLP-1 (7-36)NH 2 Example 393 (Aib 8 , β-Ala 35 , Arg 37 )hGLP-1(7-37)NH 2 Example 394 (Aib 8 , Phe 31 , β-Ala 35 )hGLP-1 (7-36)NH 2 Example 395 (Aib 835 , Phe 31 )hGLP-1(7-36)NH 2 Example 396 (Aib 835 , Nal 31 )hGLP-1 (7-36)NH 2 Example 397 (Aib 835 , Nal 28 ' 31 )hGLP-1(7-36)NH 2 Example 398 (Aib 835 , Arg 2634 , Nal 3 )hGLP-1 (7-36)NH 2 Example 399 (Aib 835 , Arg 2634 , Phe 31 )hGLP-1 (7-36)NH 2 Example 400 (Aib 835 , Nal 19 - 31 )hGLP-1(7-36)NH 2 Example 401 (Aib 835 , Nal 12 - 31 )hGLP-1 (7-36)NH 2 Example 402 (Aib 835 , Lys 36 (N ε -decanoyl))hGLP-1 (7-36) NH 2 Example 403 (Aib 835 , Arg 34 , Lys 26 (N ε -decanoyl))hGLP-1 (7-36)NH 2 Example 404 (Aib 835 , Arg 2634 , Lys 36 (N ε -dodecanoyl))hGLP-1 (7-36)NH 2 Example 405 (Aib 8 ,B-Ala 35 ,Ser 37 (O-decanoyl))hGLP1 (7-37)-NH 2 Example 406 (Aib 8 - 27 , β-Ala 35 ' 37 , Arg 38 , Lys 39 (N ε -octanoyl))hGLP-1 (7-39)NH 2 Example 407 (Aib 8 , Arg 2634 , β-Ala 35 , Lys 37 (N ε -octanoyl))hGLP-1 (7-37)NH 2 Example 408 (Aib 8 , Arg 2634 , β-Ala 35 , Lys 37 (N ε -decanoyl))hGLP-1 (7-37)NH 2 Example 409 (Aib 8 , Arg 2634 , β-Ala 35 , Lys 37 (N ε -tetradecanoyl))hGLP-1 (7-37)NH 2 Example 410 (Aib 8 , Arg 2634 , β-Ala 35 , Lys 37 (N ε -dodecanoyl))hGLP-1 (7-37)NH 2 Example 411 (Aib 8 , Arg 2634 , β-Ala 35 , Lys 37 (N ε -dodecanoyl))hGLP-1 (8-37)NH 2 Physical data for a representative sampling of the compounds exemplified herein are given in Table 1. TABLE 1

Claims: CLAIMS What is claimed is: 1. A compound of formula (I), (R 2 R 3 )-A 7 -A 8 -A 9 -A 10 -A 11 -A 12 -A 13 -A 14 -A 15 -A 16 -A 17 -A 18 -A 19 -A 20 -A 21 -A 22 -A 23 -A 24 -A 25 -A 26 -A 27 - Λ 28_ Λ 29 Λ 30 Λ 31 Λ 32 Λ 33_ Λ 34_ Λ 35_ Λ 36 Λ 37 Λ 38 Λ 39_p1 (l) wherein A 7 is L-His, Ura, Paa, Pta, Amp, Tma-His, des-amino-His, or deleted; A 8 is Ala, D-Ala, Aib, Aec, N-Me-Ala, N-Me-D-Ala or N-Me-Gly; A 9 is Glu, N-Me-Glu, N-Me-Asp or Asp; A 10 is Gly, Aec, β-Ala or Aib; A 11 s Thr or Ser; A 12 s Phe, Aec, Aic, Aib, 3-Pal, 4-Pal, β-Nal, Cha, Trp or X 1 -Phe; A 13 s Thr or Ser; A 14 s Ser or Aib; A 15 s Asp or Glu; A 16 s Val, Aec, Aib, Leu, lie, Tie, Nle, Abu, Ala or Cha; A 17 s Ser or Thr; A 18 s Ser or Thr; A 19 s Tyr, Cha, Phe, 3-Pal, 4-Pal, Aec, β-Nal or X 1 -Phe; A 20 s Leu, Ace, Aib, Nle, lie, Cha, Tie, Val, Phe or X 1 -Phe; A 21 s Glu or Asp; A 22 s Gly, Ace, β-Ala, Glu or Aib; A 23 s Gin, Asp, Asn or Glu; A 24 s Ala, Aib, Val, Abu, Tie or Aec; A 25 s Ala, Aib, Val, Abu, Tie, Aec, Lys, Arg, hArg, Om, HN-CH((CH 2 ) n -N(R 10 R 11 ))- C(O) or HN-CH((CH 2 ) e -X 3 )-C(O); A 26 is Lys, Arg, hArg, Orn, HN-CH((CH 2 ) n -N(R 10 R 1 ))-C(O) or HN-CH((CH 2 ) e -X 3 )- C(O); A 27 is Glu Asp, Leu, Aib or Lys; A 28 is Phe, Pal, β-Nal, X 1 -Phe, Aic, Aec, Aib, Cha or Trp; A 29 is lie, Aec, Aib, Leu, Nle, Cha, Tie, Val, Abu, Ala or Phe; A 30 is Ala, Aib or Ace; A 31 is Trp, β-Nal, 3-Pal, 4-Pal, Phe, Aec, Aib or Cha; A 32 is Leu, Ace, Aib, Nle, lie, Cha, Tie, Phe, X 1 -Phe or Ala; A 33 is Val, Ace, Aib, Leu, lie, Tie, Nle, Cha, Ala, Phe, Abu, Lys or X 1 -Phe; A 34 is Lys, Arg, hArg, Orn, HN-CH((CH 2 ) n -N(R 10 R 11 ))-C(O) or HN-CH((CH 2 ) e -X 3 )- C(O); A 35 is Gly, β-Ala, D-Ala, Gaba, Ava, HN-(CH 2 ) m -C(O), Aib, Ace or a D-amino acid; A 36 is L- or D-Arg, D- or L-Lys, D- or L-hArg, D- or L-Orn, HN-CH((CH 2 ) n -N(R 10 R 11 ))- C(O), HN-CH((CH 2 ) e -X 3 )-C(O) or deleted; A 37 is Gly, β-Ala, Gaba, Ava, Aib, Aec, Ado, Arg, Asp, Aun, Aec, HN-(CH 2 ) m -C(O), HN-CH((CH 2 ) n -N(R 10 R 11 ))-C(O), a D-amino acid, or deleted; A 38 is D- or L-Lys, D- or L-Arg, D- or L-hArg, D- or L-Orn, HN-CH((CH 2 ) n -N(R 10 R 11 ))- C(O), HN-CH((CH 2 ) e -X 3 )-C(O) Ava, Ado, Aec or deleted; A 39 is D- or L-Lys, D- or L-Arg, HN-CH((CH 2 ) n -N(R 10 R 11 ))-C(O), Ava, Ado, or Aec; X 1 for each occurrence is independently selected from the group consisting of (C,- C 6 )alkyl, OH and halo; R 1 is OH, NH 2 , (C^C-soJalkoxy, or NH-X 2 -CH 2 -Z°, wherein X 2 is a (C r C 12 )hydrocarbon moiety, and Z° is H, OH, CO 2 H or CONH 2 ; -NH-C(O)-CH— N N-(CH 2 ) 2 -NH-C(O)-R 13 or -C(O)-NHR 12 , wherein X 4 is, independently for each occurrence, -C(O)-, -NH- C(O)- or -CH 2 -, and wherein f is, independently for each occurrence, an integer from 1 to 29 inclusive; each of R 2 and R 3 is independently selected from the group consisting of H, (C C 30 )alkyl, (C 2 -C 30 )aikenyl, phenyl(C 1 -C 30 )alkyl, naphthy CrCaoJalkyl, hydroxy(C r C 30 )alkyl, hydroxy(C 2 -C 30 )alkenyl, hydroxypheny C^C^alkyl, and hydroxynaphthyl(C 1 -C 30 )alkyl; or one of R 2 and R 3 is ( CH 3)2 "N - C N ( C 3)2 _ (Cr Y(CH 2 ) r -N N-(CH 2 ) q SO 2 - C 30 )acyl, (C r C 30 )alkylsulfonyl, C(O)X 5 , , or Y(CH 2 ) r -N N-(CH 2 ) q -CO- ; wherein Y is H, OH or NH 2 ; r is 0 to 4; q is 0 to 4; and X 5 is (C^C^alkyl, (C 2 -C 30 )alkenyl, pheny C CsoJalkyl, naphthyl(C 1 -C 30 )alkyl, hydroxy(C C 30 )alkyl, hydroxy(C 2 -C 30 )alkenyl, hydroxyphenyl(C 1 -C 30 )alkyl or hydroxynaphthyl(C r C 30 )alkyl; e is, independently for each occurrence, an integer from 1 to 4 inclusive; m is, independently for each occurrence, an integer from 5 to 24 inclusive; n is, independently for each occurrence, an integer from 1 to 5, inclusive; each of R 10 and R 11 is, independently for each occurrence, H, (C 1 -C 30 )alkyl, (C C 30 )acyl, (C CgoJalkylsulfonyl, -C((NH)(NH 2 )) or -C(0)-CH — N N— (CH 2 ) f -CH 3 ; and R 12 and R 13 each is, independently for each occurrence, (Cι-C 30 )alkyl; provided that: when A 7 is Ura, Paa or Pta, then R 2 and R 3 are deleted; when R 10 is (C r C 30 )acyl, (CrC^alkylsulfonyl, -C((NH)(NH 2 )) or , then R 11 is H or (C r C 30 )alkyl; (i) at least one amino acid of a compound of formula (I) is not the same as the native sequence of hGLP-1 (7-36, -37 or -38)NH 2 or hGLP-1 (7-36, -37 or -38)OH; (ii) a compound of formula (I) is not an analogue of hGLP-1 (7-36, -37 or -38)NH 2 or hGLP-1 (7-36, -37 or -38)OH wherein a single position has been substituted by Ala; (iii) a compound of formula (I) is not (Arg 2634 , Lys 38 )hGLP-1 (7-38)-E, (Lys 26 (N ε - alkanoyl))hGLP-1 (7-36, -37 or -38)-E, (Lys 34 (N ε -alkanoyl))hGLP-1 (7-36, -37 or - 38)-E, (Lys 26 ' 34 -bis(N E -alkanoyl))hGLP-1 (7-36, -37 or -38)-E, (Arg 26 , Lys 34 (N E - alkanoyl))hGLP-1 (8-36, -37 or -38)-E, (Arg 2634 , Lys 36 (N ε -alkanoyl))hGLP-1 (7-36, -37 or -38)-E or (Arg 2634 , Lys 38 (N ε -aikanoyl))hGLP-1 (7-38)-E, wherein E is -OH or -NH 2 ; (iv) a compound of formula (I) is not Z 1 -hGLP-1 (7-36, -37 or -38)-OH, Z 1 -hGLP-1 (7- 36, -37 or -38)-NH 2 , wherein Z 1 is selected from the group consisting of: (e) (Arg 26 ), (Arg 34 ), (Arg 2634 ), (Lys 36 ), (Arg 26 , Lys 36 ), (Arg 34 , Lys 36 ), (D-Lys 36 ), (Arg 35 ), (D-Arg 36 ), (Arg 2634 , Lys 36 ) or (Arg 2636 , Lys 34 ); (f) (Asp 21 ); (g) at least one of (Aib 8 ), (D-Ala 8 ) and (Asp 9 ); and (h) (Tyr 7 ), (N-acyl-His 7 ), (N-alkyl-His 7 ), (N-acyl-D-His 7 ) or (N-alkyl-D-His 7 ); (v) a compound of formula (I) is not a combination of any two of the substitutions listed in groups (a) to (d); and (vi) a compound of formula (I) is not (N-Me-Ala 8 )hGLP-1 (8-36 or -37), (Glu 15 )hGLP- 1(7-36 or -37), (Asp 21 )hGLP-1(7-36 or -37) or (Phe 31 )hGLP-1 (7-36 or -37) or a pharmaceutically acceptable salt thereof. 2. A compound according to claim 1 , wherein A 11 is Thr; A 13 is Thr; A 15 is Asp; A 17 is Ser; A 18 is Ser; A 21 is Glu; A 23 is Gin or Glu; A 27 is Glu; and A 31 is Trp; or a pharmaceutically acceptable salt thereof. 3. A compound according to claim 2, wherein A 9 is Glu, N-Me-Glu or N- Me-Asp; A 12 is Phe, Aec or Aic; A 16 is Val, Ace or Aib; A 19 is Tyr; A 20 is Leu, Ace or Cha; A 24 is Ala, Aib or Ace; A 25 is Ala, Aib, Ace, Lys, Arg, hArg, Orn, HN-CH((CH 2 ) n - N(R 10 R 11 ))-C(O) or HN-CH((CH 2 ) e -X 3 )-C(O); A 28 is Phe; A 29 is lie or Ace; A 30 is Ala or Aib; A 32 is Leu, Ace or Cha; and A 33 is Val or Aec; or a pharmaceutically acceptable salt thereof. 4. A compound according to claim 3, wherein A 8 is Ala, D-Ala, Aib, A6c, A5c, N-Me-Ala, N-Me-D-Ala or N-Me-Gly; A 10 is Gly; A 12 is Phe, A6c or A5c; A 16 is Val, A6c or A5c; A 20 is Leu, A6c, A5c or Cha; A 22 is Gly, β-Ala or Aib; A 24 is Ala or Aib; A 29 is lie, A6c or A5c; A 32 is Leu, A6c, A5c or Cha; A 33 is Val, A6c or A5c; A 35 is Aib, β-Ala, Ado, A6c, A5c or Gly; and A 37 is Gly, Aib, β-Ala, Ado, D-Ala or deleted; or a pharmaceutically acceptable salt thereof. 5. A compound according to claim 4 or a pharmaceutically acceptable salt thereof, wherein X 4 for each occurrence is -C(O)-; e for each occurrence is independently 1 or 2; and R 1 is OH or NH 2 . 6. A compound according to claim 5 or a pharmaceutically acceptable salt thereof, wherein R 2 is H and R 3 is (C.,-C 3 o)alkyl, (C 2 -C 30 )alkenyl, (C r C 30 )acyl, (C r C 30 )alkylsulfonyl, ~~ λ / ~ Λ HO-(CH 2 ) 2 -N N-(CH 2 ) 2 SO 2 - HO-(CH 2 ) 2 -N N-CH 2 -CO- or / ~ ~ \ H 2 N-(CH 2 ) 2 -N N-CH 2 -CO- 7. A compound according to claim 5 or a pharmaceutically acceptable salt thereof, wherein R 10 is (C r C 30 )acyl, (CrC^alkylsulfonyl or -C(0)-CH 2 — N — (CH 2 ) f -CH 3 ' , and R 11 is H. 8. A compound according to claim 7 or a pharmaceutically acceptable salt thereof, wherein R 10 is (C 4 -C 20 )acyl, (C 4 -C 20 )alkylsulfonyl or / \ -C(0)-CH — NN NN— (CH 2 ) f -CH 3 \ / 9. A compound according to claim 1 wherein said compound is (Aib 8 ' 35 )hGLP-1(7-36)NH 2 , ((N -HEPES-His) 7 , Aib 835 )hGLP-1 (7-36)NH 2 , ((Nα-HEPA-His) 7 , Aib 8 - 35 )hGLP-1 (7-36)NH 2 , (Aib 8 , β-Ala 35 )hGLP-1 (7-36)NH 2 , (Aib 835 , Arg 2634 , Lys 36 (Nε-tetradecanoyl))hGLP-1 (7-36)NH 2 , (Aib 835 , Arg 26 , Lys 34 (Nε-tetradecanoyl))hGLP-1 (7-36)NH 2 , (Aib 835 ' 37 , Arg 26 ' 34 , Lys 38 (N ε -tetradecanoyl))hGLP-1 (7-38)NH 2 , (Aib 835 , Arg 2634 , Lys 36 (Nε-decanoyl))hGLP-1(7-36)NH 2 , (Aib 835 , Arg 26 - 34 , Lys 36 (Nε-dodecanesulfonyl))hGLP-1(7-36)NH 2 , (Aib 835 , Arg 26 - 34 , Lys 36 (N ε -(2-(4-tetradecyl-1 -piperazine)-acetyl)))hGLP-1 (7-36)NH 2 , (Aib 835 , Arg 2634 , Asp 36 (1-(4-tetradecyl-piperazine)))hGLP-1 (7-36)NH 2 , (Aib 8 - 35 , Arg 26 - 34 , Asp 36 (1-tetradecyiamino))hGLP-1 (7-36)NH 2 , (Aib 835 , Arg 26 ' 34 , Lys 36 (N ε -tetradecanoyl),β-Ala 37 )hGLP-1 (7-37)-OH or (Aib 835 , Arg 2634 , Lys 36 (N ε -tetradecanoyl))hGLP-1 (7-36)-OH, or a pharmaceutically acceptable salt thereof. 10. A compound according to claim 9 wherein said compound is (Aib 8 ' 35 )hGLP-1 (7-36)NH 2 , (Aib 8 , β-Ala 35 )hGLP-1 (7-36)NH 2 , (Aib 8 - 35 , Arg 26 , Lys 34 (Nε-tetradecanoyl))hGLP-1 (7-36)NH 2 , (Aib 8 - 35 - 37 , Arg 26 - 34 , Lys 38 (N ε -tetradecanoyl))hGLP-1 (7-38)NH 2 , (Aib 8 - 35 , Arg 26 - 34 , Lys 36 (N ε -decanoyl))hGLP-1 (7-36)NH 2 , or (Aib 8 - 35 , Arg 26 - 34 , Lys 36 (N ε -tetradecanoyl),β-Ala 37 )hGLP-1(7-37)-OH, or a pharmaceutically acceptable salt thereof. 11. A pharmaceutical composition comprising an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent. 12. A method of eliciting an agonist effect from a GLP-1 receptor in a subject in need thereof which comprises administering to said subject an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof. 13. A method of treating a disease selected from the group consisting of Type I diabetes, Type II diabetes, obesity, glucagonomas, secretory disorders of the airway, metabolic disorder, arthritis, osteoporosis, central nervous system disease, restenosis and neurodegenerative disease, in a subject in need thereof which comprises administering to said subject an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof. 14. A method according to claim 13 wherein said disease is Type I diabetes or Type II diabetes. 15. A compound according to claim 1 wherein said compound is (Aib 35 )hGLP-1 (7-36)NH 2 ; (β-Ala 35 )hGLP-1 (7-36)NH 2 ; ((N α -Me-His) 7 , Aib 8 - 35 )hGLP-1(7-36)NH 2 ; ((N α -Me-His) 7 , Aib 8 , β-Ala 35 )hGLP-1(7-36)NH 2 ; ((N α -Me-His) 7 , Aib 835 , Arg 26 ' 34 )hGLP-1(7-36)NH 2 ; ((N α -Me-His) 7 , Aib 8 , Arg 2634 , β-Ala 35 )hGLP-1(7-36)NH 2 ; (Aib 8 , A6c 35 )hGLP-1 (7-36)NH 2 ; (Aib 8 , A5c 35 )hGLP-1(7-36)NH 2 ; (Aib 8 , D-Ala 35 )hGLP-1 (7-36)NH 2 ; (Aib 835 , A6c 32 )hGLP-1 (7-36)NH 2 ; (Aib 835 , A5c 32 )hGLP-1 (7-36)NH 2 ; (Aib 835 , Glu 23 )hGLP-1 (7-36)NH 2 ; (Aib 8 - 24 - 35 )hGLP-1(7-36)NH 2 ; (Aib 8 ' 30 ' 35 )hGLP-1(7-36)NH 2 ; (Aib 8 ' 25 - 35 )hGLP-1(7-36)NH 2 ; (Aib 835 , A6c 16 ' 20 )hGLP-1 (7-36)NH 2 ; (Aib 835 , A6c 16 ' 2932 )hGLP-1(7-36)NH 2 ; (Aib 835 , A6c 20 ' 32 )hGLP-1 (7-36)NH 2 ; (Aib 835 , A6c 0 )hGLP-1(7-36)NH 2 ; (Aib 835 , Lys 25 )hGLP-1(7-36)NH 2 ; (Aib 8 ' 2435 , A6c 20 )hGLP-1 (7-36)NH 2 ; (Aib 835 , A6c 2932 )hGLP-1 (7-36)NH 2 ; (Aib 8 ' 2435 , A6c 932 )hGLP-1 (7-36)NH 2 ; (Aib 835 , A6c 12 )hGLP-1(7-36)NH 2 ; (Aib 835 , Cha 20 )hGLP-1(7-36)NH 2 ; (Aib 835 , A6c 33 )hGLP-1(7-36)NH 2 ; (Aib 835 , A6c 20 ' 32 )hGLP-1(7-36)NH 2 ; (Aib 8 , A6c 16 ' 20 , β-Ala 35 )hGLP-1(7-36)NH 2 ; (Aib 835 , β-Ala 22 )hGLP-1 (7-36)NH 2 ; (Aib 822 ' 35 )hGLP-1(7-36)NH 2 ; (Aib 8 - 35 , Glu 23 , A6c 32 )hGLP-1(7-36)NH 2 ; (Aib 8 - 24 - 35 , Glu 23 , A6c 32 )hGLP-1 (7-36)NH 2 ; (Aib 8 - 24 - 25 - 35 , Glu 23 , A6c 32 )hGLP-1(7-36)NH 2 ; (Aib 8 - 24 - 25 - 35 , A6c 16 ' 20 ' 32 , Glu 23 )hGLP-1(7-36)NH 2 ; (Aib 8 , A6c 32 , β-Ala 35 )hGLP-1(7-36)NH 2 ; (Aib 8 , A5c 32 , β-Ala 35 )hGLP-1(7-36)NH 2 ; (Aib 8 , Glu 23 , β-Ala 35 )hGLP-1(7-36)NH 2 ; (Aib 824 , β-Ala 35 )hGLP-1 (7-36)NH 2 ; (Aib 830 , β-Ala 35 )hGLP-1 (7-36)NH 2 ; (Aib 825 , β-Ala 35 )hGLP-1 (7-36)NH 2 ; (Aib 8 , A6c 16 ' 20 , β-Ala 35 )hGLP-1(7-36)NH 2 ; (Aib 8 , A6c 16 ' 29 ' 32 , β-Ala 35 )hGLP-1 (7-36)NH 2 ; (Aib 8 , A6c 20 ' 32 , β-Ala 35 )hGLP-1(7-36)NH 2 ; (Aib 8 , A6c 20 , β-Ala 35 )hGLP-1(7-36)NH 2 ; (Aib 8 , Lys 25 , β-Ala 35 )hGLP-1(7-36)NH 2 ; (Aib 824 , A6c 20 , β-Ala 35 )hGLP-1(7-36)NH 2 ; (Aib 8 , A6c 29 - 32 , β-Ala 35 )hGLP-1(7-36)NH 2 ; (Aib 8 - 24 , A6c 29 - 32 , β-Ala 35 )hGLP-1(7-36)NH 2 ; (Aib 8 , A6c 12 , β-Ala 35 )hGLP-1(7-36)NH 2 ; (Aib 8 , Cha 20 , β-Ala 35 )hGLP-1(7-36)NH 2 ; (Aib 8 , A6c 33 , β-Ala 35 )hGLP-1(7-36)NH 2 ; (Aib 8 , A6c 20 - 32 , β-Ala 35 )hGLP-1(7-36)NH 2 ; (Aib 8 , β-Ala 22 ' 35 )hGLP-1 (7-36)NH 2 ; (Aib 822 , β-Ala 35 )hGLP-1 (7-36)NH 2 ; (Aib 8 , Glu 23 , A6c 32 , β-Ala 35 )hGLP-1(7-36)NH 2 ; (Aib 824 , Glu 23 , A6c 32 , β-Ala 35 )hGLP-1 (7-36)NH 2 ; (Aib 824 , Glu 23 , A6c 32 , Lys 34 (N ε -octanoyl), β-Ala 35 )hGLP-1(7-36)NH 2 ; (Aib 824 ' 25 , Glu 23 , A6c 32 , β-Ala 35 )hGLP-1(7-36)NH 2 ; (Aib 824 ' 25 , A6c 16 ' 20 - 32 , Glu 23 , β-Ala 35 )hGLP-1(7-36)NH 2 ; (Aib 8 - 35 , D-Arg 36 )hGLP-1 (7-36)NH 2 ; (Aib 835 , D-Lys 36 )hGLP-1(7-36)NH 2 ; (Aib 8 , β-Ala 35 , D-Arg 36 )hGLP-1(7-36)NH 2 ; (Aib 8 , β-Ala 35 , D-Lys 36 )hGLP-1(7-36)NH 2 ; (Aib 835 , Arg 2634 )hGLP-1 (7-36)NH 2 ; (Aib 8 , Arg 26 - 34 , β-Ala 35 )hGLP-1 (7-36)NH 2 ; (Aib 835 , Arg 25 ' 26 ' 34 )hGLP-1(7-36)NH 2 ; (Aib 8 , Arg 2526 - 34 , β-Ala 35 )hGLP-1(7-36)NH 2 ; (Aib 8 , Arg 26 - 34 , β-Ala 35 , Lys 36 (N E -tetradecanoyl))hGLP-1(7-36)OH; (Aib 8 - 35 , Arg 26 - 34 , Lys 36 (N ε -tetradecanoyl))hGLP-1(7-37)OH; (Aib 8 - 35 - 37 , Arg 2634 , Lys 36 (N ε -tetradecanoyl))hGLP-1(7-37)OH; (Aib 835 , Arg 2634 , Lys 36 (N ε -tetradecanoyl), D-Ala 37 )hGLP-1 (7-37)OH; (Aib 835 ' 37 , Arg 2634 , Lys 38 (N ε -tetradecanoyl))hGLP-1(7-38)OH; (Aib 835 , Arg 2634 , β-Ala 37 , Lys 38 (N ε -tetradecanoyl))hGLP-1(7-38)OH; (Aib 835 , Arg 2634 , Lys 38 (N ε -tetradecanoyl))hGLP-1(7-38)OH; (Aib 8 , Arg 2634 , Lys 36 (N ε -tetradecanoyl), β-Ala 37 )hGLP-1(7-37)OH; (Aib 837 , Arg 2634 , Lys 36 (N ε -tetradecanoyl))hGLP-1(7-37)OH; (Aib 835 , Arg 2634 , Ado 37 )hGLP-1(7-37)OH; (Aib 835 , Arg 2634 , Ado 37 )hGLP-1(7-37)NH 2 ; (Aib 8 , Arg 26 - 34 , Lys 36 (N ε -tetradecanoyl), D-Ala 37 )hGLP-1(7-37)OH; (Aib 837 , Arg 2634 , Lys 38 (N ε -tetradecanoyl))hGLP-1 (7-38)OH; (Aib 8 , Arg 2634 , β-Ala 37 , Lys 38 (N ε -tetradecanoyl))hGLP-1 (7-38)OH; (Aib 835 , Lys 26 (N ε -octanoyl))hGLP-1 (7-36)NH 2 ; (Aib 835 , Lys 26 (N ε -tetradecanoyl))hGLP-1 (7-36)NH 2 ; (Aib 835 , Lys 26 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 ; (Aib 8 , Lys 26 (N ε -octanoyl), β-Ala 35 )hGLP-1(7-36)NH 2 ; (Aib 8 , Lys 26 (N E -tetradecanoyl), β-Ala 35 )hGLP-1 (7-36)NH 2 ; (Aib 8 , Lys 26 (N ε -hexadecanoyl), β-Ala 35 )hGLP-1(7-36)NH 2 ; (Aib 835 , Lys 26 (N ε -octanoyl), Arg 34 )hGLP-1 (7-36)NH 2 ; (Aib 835 , Lys 26 (N ε -tetradecanoyl), Arg 34 )hGLP-1 (7-36)NH 2 ; (Aib 835 , Lys 26 (N ε -hexadecanoyl), Arg 34 )hGLP-1 (7-36)NH 2 ; (Aib 835 , Lys 26 (N ε -decanoyl), Arg 34 )hGLP-1 (7-36)NH 2 ; (Aib 835 , Lys 25 , Lys 26 (N £ -octanoyl), Arg 3 )hGLP-1 (7-36)NH 2 ; (Aib 835 , Lys 25 , Lys 26 (N ε -tetradecanoyl), Arg 34 )hGLP-1(7-36)NH 2 ; (Aib 835 , Lys 25 , Lys 26 (N ε -hexadecanoyl), Arg 34 )hGLP-1(7-36)NH 2 ; (Aib 835 , Arg 2534 , Lys 26 (N ε -octanoyl))hGLP-1 (7-36)NH 2 ; (Aib 835 , Arg 2534 , Lys 26 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 ; (Aib 835 , Arg 2534 , Lys 26 (N ε -hexadecanoyl))hGLP-1 (7-36)NH 2 ; (Aib 835 , Arg 2534 , Lys 26 (N ε -decanoyl))hGLP-1 (7-36)NH 2 ; (Aib 8 , Lys 26 (N ε -octanoyl), Arg 34 , β-Ala 35 )hGLP-1 (7-36)NH 2 ; (Aib 8 , Lys 26 (N ε -tetradecanoyl), Arg 34 , β-Ala 35 )hGLP-1 (7-36)NH 2 ; (Aib 8 , Lys 26 (N ε -hexadecanoyl), Arg 34 , β-Ala 35 )hGLP-1 (7-36)NH 2 ; (Aib 8 , Lys 26 (N ε -decanoyl), Arg 34 , β-Ala 35 )hGLP-1 (7-36)NH 2 ; (Aib 835 , Lys 34 (N ε -octanoyl))hGLP-1 (7-36)NH 2 ; (Aib 835 , Lys 34 (N ε -tetradecanoyl))hGLP-1 (7-36)NH 2 ; (Aib 835 , Lys 34 (N ε -hexadecanoyl))hGLP-1 (7-36)NH 2 ; (Aib 835 , Arg 26 , Lys 34 (N ε -octanoyl))hGLP-1 (7-36)NH 2 ; (Aib 835 , Arg 26 , Lys 34 (N ε -hexadecanoyl))hGLP-1 (7-36)NH 2 ; (Aib 835 , Arg 26 , Lys 34 (N ε -decanoyl))hGLP-1 (7-36)NH 2 ; (Aib 8 35 , Arg 2526 , Lys 34 (N ε -octanoyl))hGLP-1 (7-36)NH 2 ; (Aib 835 , Arg 2526 , Lys 34 (N ε -tetradecanoyl))hGLP-1 (7-36)NH 2 ; (Aib 835 , Arg 2526 , Lys 3 (N ε -hexadecanoyl))hGLP-1 (7-36)NH 2 ; (Aib 8 - 35 , Arg 2526 , Lys 34 (N ε -decanoyl))hGLP-1(7-36)NH 2 ; (Aib 8 - 35 , Lys 25 , Arg 26 , Lys 34 (N ε -octanoyl))hGLP-1(7-36)NH 2 ; (Aib 8 - 35 , Lys 25 , Arg 26 , Lys 34 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 ; (Aib 835 , Lys 25 , Arg 26 , Lys 34 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 ; (Aib 8 - 35 , Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 ; (Aib 8 - 35 , Lys 36 (N ε -tetradecanoyl))hGLP-1 (7-36)NH 2 ; (Aib 8 - 35 , Lys 36 (N ε -hexadecanoyl))hGLP-1 (7-36)NH 2 ; (Aib 8 - 35 , Arg 26 , Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 ; (Aib 8 - 35 , Arg 26 , Lys 36 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 ; (Aib 835 , Arg 26 , Lys 36 (N ε -hexadecanoyl))hGLP-1 (7-36)NH 2 ; (Aib 835 , Arg 2634 , Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 ; (Aib 835 , Arg 2634 , Lys 36 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 ; (Aib 835 , Arg 2634 , Lys 38 (N ε -octanoyl))hGLP-1(7-38)NH 2 ; (Aib 835 , Arg 2634 , Lys 38 (N ε -decanoyl))hGLP-1(7-38)NH 2 ; (Aib 835 , Arg 26 - 34 , Lys 38 (N ε -tetradecanoyl))hGLP-1 (7-38)NH 2 ; (Aib 8 - 35 , Arg 26 - 34 , Lys 38 (N ε -hexadecanoyl))hGLP-1(7-38)NH 2 ; (Aib 8 - 35 - 37 , Arg 25 - 2634 , Lys 38 (N ε -octanoyl))hGLP-1(7-38)NH 2 ; (Aib 8 ' 3537 , Arg 2526 ' 34 , Lys 38 (N ε -decanoyl))hGLP-1(7-38)NH 2 ; (Aib 8 - 35 ' 37 , Arg 252634 , Lys 38 (N ε -tetradecanoyl))hGLP-1 (7-38)NH 2 ; (Aib 8 ' 3537 , Arg 252634 , Lys 38 (N ε -hexadecanoyl))hGLP-1 (7-38)NH 2 ; (Aib 8 - 3537 , Arg 2634 , Lys 38 (N ε -octanoyl))hGLP-1(7-38)NH 2 ; (Aib 8 - 35 - 37 , Arg 2634 , Lys 38 (N ε -decanoyl))hGLP-1(7-38)NH 2 ; (Aib 835 - 37 , Arg 2634 , Lys 38 (N ε -hexadecanoyl))hGLP-1(7-38)NH 2 ; (Aib 8 - 35 - 37 , Arg 2526 - 34 , Lys 38 (N ε -octanoyl))hGLP-1(7-38)NH 2 ; (Aib 8 - 35 - 37 , Arg 2526 - 34 , Lys 38 (N ε -decanoyl))hGLP-1 (7-38)NH 2 ; (Aib 8 - 35 - 37 , Arg 2526 - 34 , Lys 38 (N ε -tetradecanoyl))hGLP-1 (7-38)NH 2 ; (Aib 8 - 3537 , Arg 252634 , Lys 38 (N ε -hexadecanoyl))hGLP-1 (7-38)NH 2 ; (Aib 835 , Lys 25 , Arg 26 ' 34 , Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 ; (Aib 835 , Lys 25 , Arg 2634 , Lys 36 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 ; (Aib 835 , Lys 25 , Arg 2634 , Lys 36 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 ; (Aib 835 , Arg 252634 , Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 ; (Aib 8 - 35 , Arg 252634 , Lys 36 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 ; (Aib 8 ' 35 , Arg 25 634 , Lys 36 (N ε -hexadecanoyl))hGLP-1 (7-36)NH 2 ; (Aib 8 35 , Arg 2526 ' 34 , Lys 36 (N ε -decanoyl))hGLP-1(7-36)NH 2 ; (Aib 8 , Lys 34 (N ε -octanoyl), β-Ala 35 )hGLP-1(7-36)NH 2 ; (Aib 8 , Lys 34 (N ε -tetradecanoyl), β-Ala 35 )hGLP-1(7-36)NH 2 ; (Aib 8 , Lys 34 (N ε -hexadecanoyl), β-Ala 35 )hGLP-1(7-36)NH 2 ; (Aib 8 , A6c 32 , Lys 34 (N E -octanoyl), β-Ala 35 )hGLP-1 (7-36)NH 2 ; (Aib 8 , Glu 23 , Lys 34 (Nε-octanoyl), β-Ala 35 )hGLP-1 (7-36)NH 2 ; (Aib 8 , Glu 23 , A6c 32 , Lys 34 (N ε -octanoyl), β-Ala 35 )hGLP-1(7-36)NH 2 ; (Aib 8 , Arg 26 , Lys 34 (N ε -octanoyl), β-Ala 35 )hGLP-1 (7-36)NH 2 ; (Aib 8 , Arg 26 , Lys 34 (N e -tetradecanoyl), β-Ala 35 )hGLP-1 (7-36)NH 2 ; (Aib 8 , Arg 26 , Lys 34 (N ε -hexadecanoyl), β-Ala 35 )hGLP-1 (7-36)NH 2 ; (Aib 8 , Arg 26 , Lys 34 (N ε -decanoyl), β-Ala 35 )hGLP-1 (7-36)NH 2 ; (Aib 8 , Arg 2526 , Lys 34 (N ε -octanoyl), β-Ala 35 )hGLP-1(7-36)NH 2 ; (Aib 8 , Arg 2526 , Lys 34 (N ε -tetradecanoyl), β-Ala 35 )hGLP-1 (7-36)NH 2 ; (Aib 8 , Arg 2526 , Lys 34 (N ε -hexadecanoyl), β-Ala 35 )hGLP-1 (7-36)NH 2 ; (Aib 8 , Arg 25 - 26 , Lys 34 (N ε -decanoyl), β-Ala 35 )hGLP-1(7-36)NH 2 ; (Aib 8 , Lys 25 , Arg 26 , Lys 34 (N ε -octanoyl), β-Ala 35 )hGLP-1 (7-36)NH 2 ; (Aib 8 , Lys 25 , Arg 26 , Lys 34 (N ε -tetradecanoyl), β-Ala 35 )hGLP-1 (7-36)NH 2 ; (Aib 8 , Lys 25 , Arg 26 , Lys 34 (N ε -hexadecanoyl), β-Ala 35 )hGLP-1 (7-36)NH 2 ; (Aib 8 , β-Ala 35 , Lys 36 (N ε -octanoyl))hGLP-1 (7-36)NH 2 ; (Aib 8 , β-Ala 35 , Lys 36 (N ε -tetradecanoyl))hGLP-1 (7-36)NH 2 ; (Aib 8 , β-Ala 35 , Lys 36 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 ; (Aib 8 , Arg 26 , β-Ala 35 , Lys 36 (N ε -octanoyl))hGLP-1 (7-36)NH 2 ; (Aib 8 , Arg 26 , β-Ala 35 , Lys 36 (N ε -tetradecanoyl))hGLP-1 (7-36)NH 2 ; (Aib 8 , Arg 26 , β-Ala 35 , Lys 36 (N ε -hexadecanoyl))hGLP-1 (7-36)NH 2 ; (Aib 8 , Arg 26 - 34 , β-Ala 35 , Lys 36 (N ε -octanoyl))hGLP-1 (7-36)NH 2 ; (Aib 8 , Arg 2634 , β-Ala 35 , Lys 36 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 ; (Aib 8 , Arg 2634 , β-Ala 35 , Lys 36 (N ε - hexadecanoyl))hGLP-1 (7-36)NH 2 ; (Aib 8 , Arg 2634 , β-Ala 35 , Lys 36 (N ε -decanoyl))hGLP-1(7-36)NH 2 ; (Aib 8 , Lys 25 , Arg 2634 , β-Ala 35 , Lys 36 (N ε -octanoyl))hGLP-1 (7-36)NH 2 ; (Aib 8 , Lys 25 , Arg 2634 , Lys 36 (N ε -tetradecanoyl), β-Ala 35 )hGLP-1 (7-36)NH 2 ; (Aib 8 , Lys 25 , Arg 2634 , β-Ala 35 , Lys 36 (N ε -hexadecanoyl))hGLP-1 (7-36)NH 2 ; (Aib 8 , Arg 252634 , β-Ala 35 , Lys 36 (N ε -octanoyl))hGLP-1 (7-36)NH 2 ; (Aib 8 , Arg 25 - 2634 , β -Ala 35 , Lys 36 (N ε -tetradecanoyl))hGLP-1 (7-36)NH 2 ; (Aib 8 , Arg 252634 , β-Ala 35 , Lys 36 (N ε -hexadecanoyl))hGLP-1 (7-36)NH 2 ; (Aib 8 , Arg 252634 , β-Ala 35 , Lys 36 (N ε -decanoyl))hGLP-1 (7-36)NH 2 ; (Aib 835 , Lys 26 (N ε -octanoyl), A6c 32 , Arg 34 )hGLP-1 (7-36)NH 2 ; (Aib 835 , Lys 26 (N ε -tetradecanoyl), A6c 32 , Arg 34 )hGLP-1 (7-36)NH 2 ; (Aib 835 , Lys 26 (N ε -hexadecanoyl), A6c 32 , Arg 34 )hGLP-1 (7-36)NH 2 ; (Aib 835 , A6c 32 , Lys 34 (N ε -octanoyl))hGLP-1 (7-36)NH 2 ; (Aib 835 , A6c 32 , Lys 34 (N ε -tetradecanoyl))hGLP-1 (7-36)NH 2 ; (Aib 8 35 , A6c 32 , Lys 34 (N ε -hexadecanoyl))hGLP-1 (7-36)NH 2 ; (Aib 835 , Arg 26 , A6c 32 , Lys 34 (N ε -octanoyl))hGLP-1 (7-36)NH 2 ; (Aib 835 , Arg 26 , A6c 32 , Lys 34 (N ε -tetradecanoyl))hGLP-1 (7-36)NH 2 ; (Aib 835 , A6c 32 , Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 ; (Aib 835 , A6c 32 , Lys 36 (N ε -tetradecanoyl))hGLP-1 (7-36)NH 2 ; (Aib 835 , A6c 32 , Lys 36 (N ε -hexadecanoyl))hGLP-1 (7-36)NH 2 ; (Aib 835 , Arg 26 , A6c 32 , Lys 36 (N ε -octanoyl))hGLP-1 (7-36)NH 2 ; (Aib 8 35 , Arg 26 , A6c 32 , Lys 36 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 ; (Aib 835 , Arg 26 , A6c 32 , Lys 36 (N ε -hexadecanoyl))hGLP-1 (7-36)NH 2 ; (Aib 8 - 35 , Arg 26 - 34 , A6c 32 , Lys 36 (N ε -octanoyl))hGLP-1 (7-36)NH 2 ; (Aib 8 - 35 , Arg 26 - 34 , A6c 32 , Lys 36 (N ε -decanoyl))hGLP-1 (7-36)NH 2 ; (Aib 8 - 35 , Arg 2634 , A6c 32 , Lys 36 (N ε -tetradecanoyl))hGLP-1 (7-36)NH 2 ; (Aib 835 , Arg 2634 , A6c 32 , Lys 36 (N ε -hexadecanoyl))hGLP-1 (7-36)NH 2 ; (Aib 8 24 ' 35 , Lys 26 (N ε -octanoyl), Arg 34 )hGLP-1 (7-36)NH 2 ; (Aib 8 ' 2435 , Lys 26 (N ε -tetradecanoyl), Arg 34 )hGLP-1 (7-36)NH 2 ; (Aib 8 ' 2435 , Lys 26 (N ε -hexadecanoyl), Arg 34 )hGLP-1 (7-36)NH 2 ; (Aib 8 - 24 - 35 , Arg 26 , Lys 34 (N ε -octanoyl))hGLP-1 (7-36)NH 2 ; (Aib 824 ' 35 , Arg 26 , Lys 34 (N ε -tetradecanoyl))hGLP-1 (7-36)NH 2 ; (Aib 8 ' 2435 , Arg 26 , Lys 34 (N ε -hexadecanoyl))hGLP-1 (7-36)NH 2 ; (Aib 8 ' 2435 , Arg 2634 , Lys 36 (N ε -octanoyl))hGLP-1 (7-36)NH 2 ; (Aib 8 ' 2435 , Arg 2634 , Lys 36 (N ε -tetradecanoyl))hGLP-1 (7-36)NH 2 ; (Aib 82435 , Arg 26 - 34 , Lys 36 (N ε -hexadecanoyl))hGLP-1 (7-36)NH 2 ; (Aib 8 - 24 - 35 , Glu 23 , A6c 32 , Lys 34 (Nε-octanoyl))hGLP-1 (7-36)NH 2 ; (Aib 8 - 35 , Glu 23 , Lys 26 (N ε -octanoyl), Arg 34 )hGLP-1(7-36)NH 2 ; (Aib 8 - 35 , Glu 23 , Lys 26 (N ε -tetradecanoyl), Arg 34 )hGLP-1(7-36)NH 2 ; (Aib 8 - 35 , Glu 23 , Lys 26 (N ε -hexadecanoyl), Arg 34 )hGLP-1(7-36)NH 2 ; (Aib 8 - 35 , Glu 23 , Lys 34 (N ε -octanoyl))hGLP-1(7-36)NH 2 ; (Aib 8 - 35 , Glu 23 , A6c 32 , Lys 34 (N ε -octanoyl))hGLP-1(7-36)NH 2 ; (Aib 8 - 35 , Glu 23 , Arg 26 , Lys 34 (N ε -octanoyl))hGLP-1 (7-36)NH 2 ; (Aib 8 - 35 , Glu 23 , Arg 26 , Lys 34 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 ; (Aib 8 - 35 , Glu 23 , Arg 26 , Lys 34 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 ; (Aib 8 - 35 , Glu 23 , Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 ; (Aib 8 - 35 , Glu 23 , Lys 36 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 ; (Aib 8 - 35 , Glu 23 , Lys 36 (N ε -hexadecanoyi))hGLP-1 (7-36)NH 2 ; (Aib 835 , Glu 23 , Arg 26 - 34 , Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 ; (Aib 835 , Glu 23 , Arg 2634 , Lys 36 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 ; (Aib 835 , Glu 23 , Arg 2634 , Lys 36 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 ; (Aib 830 ' 35 , Lys 26 (N ε -octanoyl), Arg 34 )hGLP-1 (7-36)NH 2 ; (Aib 8 - 30 - 35 , Lys 26 (N ε -tetradecanoyl), Arg 34 )hGLP-1(7-36)NH 2 ; (Aib 8 - 30 - 35 , Lys 26 (N ε -hexadecanoyl), Arg 34 )hGLP-1 (7-36)NH 2 ; (Aib 8 - 30 - 35 , Arg 26 , Lys 34 (N ε -octanoyl))hGLP-1(7-36)NH 2 ; (Aib 8 - 3035 , Arg 26 , Lys 34 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 ; (Aib 8 - 30 - 35 , Arg 26 , Lys 34 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 ; (Aib 8 ' 3035 , Arg 2634 , Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 ; (Aib 830 - 35 , Arg 2634 , Lys 36 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 ; (Aib 8 - 30 - 35 , Arg 2634 , Lys 36 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 ; (Aib 835 , Glu 23 , A6c 32 , Lys 36 (N ε -octanoyl))hGLP-1 (7-36)NH 2 ; (Aib 835 , Glu 23 , A6c 32 , Lys 36 (N ε -tetradecanoyl))hGLP-1 (7-36)NH 2 ; (Aib 835 , Glu 23 , A6c 32 , Lys 36 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 ; (Aib 835 , Glu 23 , Arg 2634 , A6c 32 , Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 ; (Aib 835 , Glu 23 , Arg 2634 , A6c 32 , Lys 36 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 ; (Aib 835 , Glu 23 , Arg 2634 , A6c 32 , Lys 36 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 ; (Aib 824 ' 35 , Glu 23 , Arg 26 ' 34 , A6c 32 , Lys 36 (N ε -octanoyl))hGLP-1 (7-36)NH 2 ; (Aib 824 - 35 , Glu 23 , Arg 2634 , A6c 32 , Lys 36 (N ε -tetradecanoyl))hGLP-1 (7-36)NH 2 ; (Aib 8 ' 2435 , Glu 23 , Arg 2634 , A6c 32 , Lys 36 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 ; (Aib 824 - 30 - 35 , Glu 23 , Arg 26 - 34 , A6c 32 , Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 ; (Aib 824 ' 3035 , Glu 23 , Arg 2634 , A6c 32 , Lys 36 (N ε -tetradecanoyl))hGLP-1 (7-36)NH 2 ; (Aib 8 - 24 ' 3035 , Glu 23 , Arg 2634 , A6c 32 , Lys 36 (N ε -hexadecanoyl))hGLP-1 (7-36)NH 2 ; ((N α -HEPES-His) 7 , Aib 35 )hGLP-1 (7-36)NH 2 ; ((N α -HEPES-His) 7 , β-Ala 35 )hGLP-1 (7-36)NH 2 ; ((N α -HEPES-His) 7 , Aib 8 , β-Ala 35 )hGLP-1 (7-36)NH 2 ; ((N α -HEPA-His) 7 , Aib 35 )hGLP-1 (7-36)NH 2 ; ((N α -HEPA-His) 7 , β-Ala 35 )hGLP-1 (7-36)NH 2 ; ((N α -HEPA-His) 7 , Aib 8 , β-Ala 35 )hGLP-1 (7-36)NH 2 ; ((N α -tetradecanoyl-His) 7 , Aib 35 )hGLP-1 (7-36)NH 2 ; ((N α -tetradecanoyl-His) 7 , β-Ala 35 )hGLP-1 (7-36)NH 2 ; ((N α -tetradecanoyl-His) 7 , Aib 8 - 35 )hGLP-1 (7-36)NH 2 ; ((N α -tetradecanoyl-His) 7 , Aib 8 , β-Ala 35 )hGLP-1(7-36)NH 2 ; ((N α -tetradecanoyl-His) 7 , Arg 26 - 34 , Aib 35 )hGLP-1 (7-36)NH 2 ; ((N α -tetradecanoyl-His) 7 , Arg 26 - 34 , β-Ala 35 )hGLP-1 (7-36)NH 2 ; ((N α -tetradecanoyl-His) 7 , Aib 8 - 35 , Arg 2634 )hGLP-1(7-36)NH 2 ; ((N α -tetradecanoyl-His) 7 , Aib 8 , Arg 26 - 34 , β-Ala 35 )hGLP-1 (7-36)NH 2 ; ((N α -tetradecanoyl-His) 7 , Arg 25 ' 26 - 34 , β-Ala 35 )hGLP-1 (7-36)NH 2 ; ((N α -tetradecanoyl-His) 7 , Aib 8 - 35 , Arg 25 - 2634 )hGLP-1 (7-36)NH 2 ; ((N α -tetradecanoyl-His) 7 , Aib 8 , Arg 252634 , β-Ala 35 )hGLP-1 (7-36)NH 2 ; (Aib 8 35 , Lys 26 (N ε -octanesulfonyl), Arg 34 )hGLP-1 (7-36)NH 2 ; (Aib 8 - 35 , Lys 26 (N ε -dodecanesulfonyl), Arg 34 )hGLP-1 (7-36)NH 2 ; (Aib 835 , Lys 6 (N ε -hexadecanesulfonyl), Arg 34 )hGLP-1(7-36)NH 2 ; (Aib 8 - 35 , Arg 26 , Lys 34 (N ε -octanesulfonyl))hGLP-1 (7-36)NH 2 ; (Aib 835 , Arg 26 , Lys 34 (N ε -dodecanesulfonyl))hGLP-1 (7-36)NH 2 ; (Aib 8 35 , Arg 26 , Lys 34 (N ε -hexadecanesulfonyl))hGLP-1 (7-36)NH 2 ; (Aib 8 35 , Arg 2634 , Lys 36 (N ε -octanesulfonyi))hGLP-1 (7-36)NH 2 ; (Aib 8 35 , Arg 2634 , Lys 36 (N ε -hexadecanesulfonyl))hGLP-1 (7-36)NH 2 ; (Aib 8 35 , Asp 26 (1-(4-decylpiperazine)), Arg 34 )hGLP-1 (7-36)NH 2 ; (Aib 8 35 , Asp 26 (1-(4-dodecylpiperazine)), Arg 34 )hGLP-1 (7-36)NH 2 ; (Aib 8 35 , Asp 26 (1 -(4-tetradecylpiperazine)), Arg 34 )hGLP-1 (7-36)NH 2 ; (Aib 835 , Asp 26 (1-(4-hexadecylpiperazine)), Arg 34 )hGLP-1 (7-36)NH 2 ; (Ajb 8,35,37 > Arg 25 . 26 . 34 _ Asp 38 (1 -(4-hexadecylpjperazine)))hGLP-1 (7-38)NH 2 ; (Aib 8 - 35 , Arg 2634 , Glu 36 (1-dodecylamino))hGLP-1 (7-36)NH 2 ; (Aib 835 , Glu 26 (1-dodecylamino), Arg 34 )hGLP-1 (7-36)NH 2 ; (Aib 835 , Arg 26 , Glu 34 (1-dodecylamino))hGLP-1(7-36)NH 2 ; (Aib 8 - 35 - 37 , Arg 2634 , Glu 38 (1-dodecylamino))hGLP-1 (7-38)NH 2 ; (Aib 8 - 35 , Arg 34 , Lys 26 (N ε -(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1 (7-36)NH 2 ; (Aib 8 - 35 , Arg 34 , Lys 26 (N ε -(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1 (7-36)NH 2 ; (Aib 8 - 35 , Arg 34 , Lys 26 (N ε -(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1 (7-36)NH 2 ; (Aib 8 - 35 , Arg 34 , Lys 26 (N ε -(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1 (7-36)NH 2 ; (Aib 8 - 35 , Arg 26 , Lys 34 (N ε -(2-(4-decyl-1 -piperazine)-acetyl)))hGLP-1 (7-36)NH 2 ; (Aib 8 - 35 , Arg 26 , Lys 34 (N ε -(2-(4-dodecyl-1-piperazine)-acetyl))hGLP-1 (7-36)NH 2 ; (Aib 835 , Arg 26 , Lys 34 (N ε -(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1 (7-36)NH 2 ; (Aib 8 - 35 , Arg 26 , Lys 34 (N ε -(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1 (7-36)NH 2 ; (Aib 8 - 35 , Arg 2634 , Lys 36 (N ε -(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1 (7-36)NH 2 ; (Aib 8 - 35 , Arg 26 - 34 , Lys 36 (N ε -(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1 (7-36)NH 2 ; (Aib 8 - 35 , Arg 26 - 34 , Lys 36 (N ε -(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1 (7-36)NH 2 ; (Aib 8 - 35 , Arg 26 - 34 , Lys 38 (N ε -(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1 (7-38)NH 2 ; (Aib 835 , Arg 2634 , Lys 38 (N ε -(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1 (7-38)NH 2 ; (Aib 835 , Arg 2634 , Lys 38 (N ε -(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1 (7-38)NH 2 ; (Aib 8 - 35 , Arg 2634 , Lys 38 (N ε -(2-(4-hexadecyl-1 -piperazine)-acetyl)))hGLP-1 (7-38)NH 2 ; (Aib 8 ' 35 ' 37 , Arg 26 - 34 , Lys 38 (N ε -(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1 (7-38)NH 2 ; (Aib 8 - 35 - 37 , Arg 26 - 34 , Lys 38 (N ε -(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1 (7-38)NH 2 ; (Aib 835 - 37 , Arg 26 - 34 , Lys 38 (N ε -(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1 (7-38)NH 2 ; (Aib 835 - 37 , Arg 2634 , Lys 38 (N ε -(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1 (7-38)NH 2 ; (Aib 835 , Arg 2534 , Lys 26 (N ε -(2-(4-decyl-1 -piperazine)-acetyl)))hGLP-1 (7-36)NH 2 ; (Aib 835 , Arg 2534 , Lys 26 (N ε -(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH 2 ; (Aib 835 , Arg 2534 , Lys 26 (N ε -(2-(4-tetradecyl-1 -piperazine)-acetyl)))hGLP-1 (7-36)NH 2 ; Aib 835 , Arg 2534 , Lys 26 (N ε -(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1 (7-36)NH 2 ; (Aib 835 , Arg 2526 , Lys 34 (N ε -(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1 (7-36)NH 2 ; (Aib 835 , Arg 25 - 26 , Lys 34 (N ε -(2-(4-dodecyl-1 -piperazine)-acetyl)))hGLP-1 (7-36)NH 2 ; (Aib 8 - 35 , Arg 2526 , Lys 34 (N ε -(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1 (7-36)NH 2 ; (Aib 835 , Arg 25 - 26 , Lys 34 (N ε -(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1 (7-36)NH 2 ; (Aib 8 - 35 , Arg 25 - 26 - 34 , Lys 36 (N ε -(2-(4-decyl-1 -piperazine)-acetyl)))hGLP-1 (7-36)NH 2 ; (Aib 8 - 35 , Arg 25 - 26 - 34 , Lys 36 (N ε -(2-(4-dodecyl-1 -piperazine)-acetyl)))hGLP-1 (7-36)NH 2 ; (Aib 8 - 35 , Arg 25 - 26 - 34 , Lys 36 (N ε -(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1 (7-36)NH 2 ; (Aib 8 - 35 , Arg 25 - 26 - 34 , Lys 36 (N ε -(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH 2 ; (Aib 835 , Arg 25 ' 2634 , Lys 38 (N ε -(2-(4-decyl-1 -piperazine)-acetyl)))hGLP-1 (7-38)NH 2 ; (Aib 8 - 35 , Arg 252634 , Lys 38 (N ε -(2-(4-dodecyl-1 -piperazine)-acetyl)))hGLP-1 (7-38)NH 2 ; (Aib 8 - 35 , Arg 25 - 2634 , Lys 38 (N ε -(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1 (7-38)NH 2 ; (Aib 835 , Arg 25 - 26 - 34 , Lys 38 (N ε -(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1 (7-38)NH 2 ; (Aib 8 ' 3537 , Arg 25 - 26 - 34 , Lys 38 (N ε -(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1 (7-38)NH 2 ; (Aib 835 ' 37 , Arg 25 - 2634 , Lys 38 (N ε -(2-(4-dodecyl-1 -piperazine)-acetyl)))hGLP-1 (7-38)NH 2 ; (Aib 8 - 35 - 37 , Arg 25 ' 26 - 34 , Lys 38 (N ε -(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1 (7- 38)NH 2 ; (Aib 83537 , Arg 252634 , Lys 38 (N ε -(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1 (7- 38)NH 2 ; (Aib 835 , Arg 2634 , Lys 36 (N ε -decanoyl))hGLP-1 (7-36)OH; (Aib 835 , Lys 25 , Arg 26 ' 34 , Lys 36 (N ε -decanoyl))hGLP-1 (7-36)OH; (Aib^.Arg 2634 , Ava 37 , Ado 38 )hGLP-1 (7-38)NH 2 ; (Aib 8 ' 35 ,Arg 26 ' 34 , Asp 37 , Ava 38 , Ado 39 )hGLP-1 (7-39)NH 2 ; (Aib 8 ' 35 ,Arg 26 ' 34 , Aun 37 )hGLP-1 (7-37)NH 2 ; (Aib 8 ' 17 ' 35 ,)hGLP-1(7-36)NH 2 ; (Aib 8 ,Arg 26 - 34 , β-Ala 35 , D-Asp 37 , Ava 38 , Aun 39 )hGLP-1(7-39)NH 2 ; (Gly 8 , β-Ala 35 )hGLP-1 (7-36)NH 2 ; (Ser 8 , β-Ala 35 )hGLP-1 (7-36)NH 2 ; (Aib 8 , Glu 22 - 23 , β-Ala 35 )hGLP-1 (7-36)NH 2 ; (Gly 8 , Aib 35 )hGLP-1 (7-36)NH 2 ; (Aib 8 , Lys 18 , β-Ala 35 )hGLP-1 (7-36)NH 2 ; (Aib 8 , Leu 27 , β-Ala 35 )hGLP-1 (7-36)NH 2 ; (Aib 8 , Lys 33 , β-Ala 35 )hGLP-1 (7-36)NH 2 ; (Aib 8 , Lys 18 , Leu 27 , β-Ala 35 )hGLP-1(7-36)NH 2 ; (Aib 8 , D-Arg 36 )hGLP-1 (7-36)NH 2 ; (Aib 8 , β-Ala 35 , D-Arg 37 )hGLP-1 (7-37)NH 2 ; (Aib 827 , β-Ala 35 )hGLP-1 (7-36)NH 2 ; (Aib 8 - 27 , β-Ala 35 - 37 , Arg 38 )hGLP-1(7-38)NH 2 ; (Aib 8 - 27 , β-Ala 35 ' 37 , Arg 3839 )hGLP-1 (7-39)NH 2 ; (Aib 8 , Lys 18 ' 27 , β-Ala 35 )hGLP-1 (7-36)NH 2 ; (Aib 8 , Lys 27 , β-Ala 35 )hGLP-1 (7-36)NH 2 ; (Aib 8 , β-Ala 35 , Arg 38 )hGLP-1 (7-38)NH 2 ; (Aib 8 , Arg 26 ' 34 , β-Ala 35 ,)hGLP-1 (7-36)NH 2 ; (Aib 8 , D-Arg 35 )hGLP-1 (7-36)NH 2 ; (Aib 8 , β-Ala 35 , Arg 37 )hGLP-1(7-37)NH 2 ; (Aib 8 , Phe 31 , β-Ala 35 )hGLP-1 (7-36)NH 2 ; (Aib 835 , Phe 31 )hGLP-1 (7-36)NH 2 ; (Aib 835 , Nal 31 )hGLP-1 (7-36)NH 2 ; (Aib 8 - 35 , Nal 28 - 31 )hGLP-1 (7-36)NH 2 ; (Aib 8 - 35 , Arg 2634 , Nal 31 )hGLP-1 (7-36)NH 2 ; (Aib 8 - 35 , Arg 26 - 34 , Phe 31 )hGLP-1 (7-36)NH 2 ; (Aib 8 - 35 , Nal 1931 )hGLP-1 (7-36)NH 2 ; (Aib 835 , Nal 12 ' 31 )hGLP-1(7-36)NH 2 ; (Aib 835 , Lys 36 (N ε -decanoyl))hGLP-1 (7-36)NH 2 ; (Aib 835 , Arg 34 , Lys 26 (N ε -decanoyl))hGLP-1 (7-36)NH 2 ; (Aib 835 , Arg 2634 , Lys 36 (N ε -dodecanoyl))hGLP-1 (7-36)NH 2 ; (Aib 8 ,B-Ala 35 ,Ser 37 (O-decanoyl))hGLP1(7-37)-NH 2 ; (Aib 827 , β-Ala 3537 , Arg 38 , Lys 39 (N ε -octanoyl))hGLP-1 (7-39)NH 2 ; (Aib 8 , Arg 2634 , β-Ala 35 , Lys 37 (N ε -octanoyl))hGLP-1 (7-37)NH 2 ; (Aib 8 , Arg 26 ' 34 , β-Ala 35 , Lys 37 (N ε -decanoyl))hGLP-1(7-37)NH 2 ; (Aib 8 , Arg 2634 , β-Ala 35 , Lys 37 (N ε -tetradecanoyl))hGLP-1(7-37)NH 2 ; (Aib 8 , Arg 26 ' 34 , β-Ala 35 , Lys 37 (N ε -dodecanoyl))hGLP-1 (7-37)NH 2 ; or (Aib 8 , Arg 2634 , β-Ala 35 , Lys 37 (N ε -dodecanoyl))hGLP-1 (8-37)NH 2 ; or a pharmaceutically acceptable salt thereof. 16. A compound according to claim 15 wherein said compound is (Aib 835 , A6c 32 )hGLP-1 (7-36)NH 2 ; (Aib 835 , Glu 23 )hGLP-1 (7-36)NH 2 ; (Aib 8 ' 2 35 )hGLP-1(7-36)NH 2 ; (Aib 8 35 , Glu 23 , A6c 32 )hGLP-1 (7-36)NH 2 ; (Aib 8 , Glu 23 , β-Ala 35 )hGLP-1 (7-36)NH 2 ; (Aib 835 , Arg 2634 )hGLP-1 (7-36)NH 2 ; (Aib 8 - 35 , Arg 2634 , Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 ; (Aib 8 - 35 , Arg 26 - 34 , Lys 36 (N ε -decanoyl))hGLP-1(7-36)OH; (Aib 8 - 35 , Lys 25 , Arg 2634 , Lys 36 (N ε -decanoyl))hGLP-1(7-36)OH; (Aib 8 , Arg 2634 , β-Ala 35 , Lys 36 (N ε -Aec-decanoyl))hGLP-1(7-36)NH 2 ; (Aib 8 ' 35 ,Arg 26 ' 34 , Ava 37 , Ado 38 )hGLP-1(7-38)NH 2 ; (Aib 8 ' 35 ,Arg 26 - 34 , Asp 37 , Ava 38 , Ado 39 )hGLP-1(7-39)NH 2 ; (Aib 8 - 35 ,Arg 26 - 34 , Aun 37 )hGLP-1 (7-37)NH 2 ; (Aib 817 ' 35 ,)hGLP-1 (7-36)NH 2 ; (Aib 8 ,Arg 26 ' 34 , β-Ala 35 , D-Asp 37 , Ava 38 , Aun 39 )hGLP-1(7-39)NH 2 ; (Gly 8 , β-Ala 35 )hGLP-1(7-36)NH 2 ; (Ser 8 , β-Ala 35 )hGLP-1(7-36)NH 2 ; (Aib 8 , Glu 2223 , β-Ala 35 )hGLP-1(7-36)NH 2 ; (Gly 8 , Aib 35 )hGLP-1(7-36)NH 2 ; (Aib 8 , Lys 18 , β-Ala 35 )hGLP-1(7-36)NH 2 ; (Aib 8 , Leu 27 , β-Ala 35 )hGLP-1(7-36)NH 2 ; (Aib 8 , Lys 33 , β-Ala 35 )hGLP-1(7-36)NH 2 ; (Aib 8 , Lys 18 , Leu 27 , β-Ala 35 )hGLP-1(7-36)NH 2 ; (Aib 8 , D-Arg 36 )hGLP-1(7-36)NH 2 ; (Aib 8 , β-Ala 35 , D-Arg 37 )hGLP-1(7-37)NH 2 ; (Aib 827 , β-Ala 35 )hGLP-1(7-36)NH 2 ; (Aib 827 , β-Ala 35 ' 37 , Arg 38 )hGLP-1(7-38)NH 2 ; (Aib 827 , β-Ala 35 ' 37 , Arg 38 ' 39 )hGLP-1(7-39)NH 2 ; (Aib 8 , Lys 1827 , β-Ala 35 )hGLP-1(7-36)NH 2 ; (Aib 8 , Lys 27 , β-Ala 35 )hGLP-1(7-36)NH 2 ; (Aib 8 , β-Ala 35 , Arg 38 )hGLP-1(7-38)NH 2 ; (Aib 8 , Arg 2634 , β-Ala 35 ,)hGLP-1(7-36)NH 2 ; (Aib 8 , D-Arg 35 )hGLP-1(7-36)NH 2 ; (Aib 8 , β-Ala 35 , Arg 37 )hGLP-1(7-37)NH 2 ; (Aib 8 , Phe 31 , β-Ala 35 )hGLP-1(7-36)NH 2 ; (Aib 8 - 35 , Phe 31 )hGLP-1(7-36)NH 2 ; (Aib 835 , Nal 31 )hGLP-1(7-36)NH 2 ; (Aib 835 , Nal 28 ' 31 )hGLP-1 (7-36)NH 2 ; (Aib 835 , Arg 2634 , Nal 31 )hGLP-1(7-36)NH 2 ; (Aib 835 , Arg 2634 , Phe 31 )hGLP-1(7-36)NH 2 ; (Aib 8 - 35 , Nal 1931 )hGLP-1 (7-36)NH 2 ; (Aib 835 , Nal 12 ' 31 )hGLP-1 (7-36)NH 2 ; (Aib 8 - 35 , Lys 36 (N ε -decanoyl))hGLP-1 (7-36) NH 2 ; (Aib 8 - 35 , Arg 34 , Lys 6 (N ε -decanoyl))hGLP-1 (7-36)NH 2 ; (Aib 8 - 35 , Arg 26 - 34 , Lys 36 (N ε -dodecanoyl))hGLP-1 (7-36)NH 2 ; (Aib 8 ,B-Ala 35 , Ser^O-decanoyl^hGLPI (7-37)-NH 2 ; (Aib 827 , β-Ala 35 - 37 , Arg 38 , Lys 39 (N ε -octanoyl))hGLP-1 (7-39)NH 2 ; (Aib 8 , Arg 26 - 34 , β-Ala 35 , Lys 37 (N ε -octanoyl))hGLP-1 (7-37)NH 2 ; (Aib 8 , Arg 26 - 34 , β-Ala 35 , Lys 37 (N ε -decanoyl))hGLP-1 (7-37)NH 2 ; or (Aib 8 , Arg 26 - 34 , β-Ala 35 , Lys 37 (N ε -tetradecanoyl))hGLP-1 (7-37)NH 2 ; or a pharmaceutically acceptable salt thereof. 17. Use of a compound as claimed in any of claims 1 to 10, or 15 or 16, in the preparation of a medicament for the treatment of disease. 18. Use as claimed in claim 17, in which the disease is selected from the group consisting of Type I diabetes, Type II diabetes, obesity, glucagonomas, secretory disorders of the airway, metabolic disorder, arthritis, osteoporosis, central nervous system disease, restenosis and neurodegenerative disease.

Inventors: DONG ZHENG XIN, DONG, ZHENG, XIN
Applicants: DONG ZHENG XIN, SOD CONSEILS RECH APPLIC, DONG, ZHENG, XIN, SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES S.A.
Application year: 1999
Main classification: C07K14
IPC codes: A61K38, A61P1, A61P3, A61P5, A61P9, A61P11, A61P13, A61P19, A61P25, A61P43, C07K14